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Spatiotemporal protein reorganization at DNA damage sites induced by genotoxic chemotherapies is crucial
for DNA damage response (DDR), which influences treatment response by directing cancer cell fate. This pro-
cess is orchestrated by valosin-containing protein (VCP), an AAA+ ATPase that extracts polyubiquinated
chromatin proteins and facilitates their turnover. However, because of the essential and pleiotropic effects
of VCP in global proteostasis, it remains challenging practically to understand and target its DDR-specific
functions. We describe a DNA-damage-induced phosphorylation event (Ser784), which selectively enhances
chromatin-associated protein degradation mediated by VCP and is required for DNA repair, signaling, and
cell survival. These functional effects of Ser784 phosphorylation on DDR correlate with a decrease in VCP
association with chromatin, cofactors NPL4/UFD1, and polyubiquitinated substrates. Clinically, high phos-
pho-Ser784-VCP levels are significantly associated with poor outcome among chemotherapy-treated breast
cancer patients. Thus, Ser784 phosphorylation is a DDR-specific enhancer of VCP function and a potential
predictive biomarker for chemotherapy treatments.
INTRODUCTION
Many anticancer chemotherapies are genotoxic and trigger
DNA-damage-induced apoptosis. Unfortunately, their effects
vary among patients, and our ability to both predict and improve
therapeutic response remains limited. This is mainly due to the
complex nature of the DNA damage response (DDR), an evolu-
tionarily conserved mechanism involving extensive protein net-
works collectively serving to repair damaged DNA and to deter-
mine cell fate. Nevertheless, mounting evidence suggests that
inherent DDR deficits and the resultant genome instability are
an ‘‘Achilles’ heel’’ of cancer, which could be effectively targeted
(Lord and Ashworth, 2012; O’Connor, 2015). The best modern
example is the clinical success of treating cancers harboring de-
fects in homologous recombination (the most faithful repair
mechanism for DNA double-strand breaks [DSBs]) with inhibi-
tors of PARP (a key repair enzyme for DNA single-strand breaks
[SSBs]) (Bryant et al., 2005; Farmer et al., 2005). Thus, identifying
cancer-specific DDR defects and understanding their mecha-
nisms can guide effective therapeutic exploitation.
All DNA breaks trigger global changes in protein post-trans-
lational modifications (PTMs) at and near damage sites. These
PTM events are tightly coordinated and together orchestrate a
rapid and orderly recruitment of DNA repair factors and
signaling molecules to DNA-damage sites to ensure the suc-
cessful execution of all functional aspects of DDR, including
DNA repair, cell cycle checkpoint activation, and transcrip-
tional, translational, and metabolic reprogramming (Dantuma
and van Attikum, 2016; Polo and Jackson, 2011). Among the
various PTMs, K48-linked polyubiquitination of various chro-
matin-binding proteins occurs rapidly and transiently at
DNA-damage sites and signals for their physical removal
and subsequent recycling or degradation by proteasomes.
Although our knowledge about the identity and functional sig-
nificance of these K48-polyubiquinated proteins remains
incomplete, it is evident that their timely removal governs pro-
teostasis at DNA-damage sites by coordinating the protein
flux between chromatin and the surrounding nuclear environ-
ment (Brinkmann et al., 2015; Brown and Jackson, 2015;
Ghosh and Saha, 2012).
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Figure 1. Nuclear Antigen Recognized by the pSer137-Pfn1 Antibody Associates with Poor Survival Among Chemotherapy-Treated Breast
Cancer Patients
(A) Representative images of the nuclear staining of human breast tumors by the pSer137-Pfn1 antibody. 20X magnification; scale bars, 100 mm.
(B–D) Univariate Kaplan-Meier analyses showing an inverse correlation between nuclear staining by the pSer137-Pfn1 antibody and patient survival in the SPECS
series (B), UBC series (C), and the TNBC subset of the UBC series (D). OS, overall survival; RFS, relapse-free survival; BCSS, breast cancer-specific survival;
TNBC, triple-negative breast cancer.
(legend continued on next page)




Certain polyubiquinated proteins, because of tight association
with membranes, DNA, and protein partners, cannot dissociate
spontaneously. In such cases, they are extracted in an energy-
dependent manner by valosin-containing protein (VCP), a highly
conserved, hexameric AAA+ ATPase essential for global cellular
proteostasis. Dubbed a protein ‘‘segregase,’’ VCP is present
throughout the cell and extracts ‘‘trapped’’ K48-polyubiquinated
proteins from various organelles (endoplasmic reticulum, mito-
chondria, and endosomes), structures (chromatin), and macro-
molecular complexes (ribosomes and aggresomes) (Meyer
et al., 2012; Meyer and Weihl, 2014). VCP function is facilitated
by multiple cofactors (e.g., p47 and NPL4/UFD1); most of which
associate with its N-terminal domain and directly bind polyubi-
quinated client proteins (Meyer et al., 2012; Meyer and Weihl,
2014; Ramadan et al., 2017; Vaz et al., 2013). The broad range
of protein substrates functionally involved in nearly all cellular
processes underlie the essentiality of VCP formultiple organisms
(Fro¨hlich et al., 1991; Lamb et al., 2001; Leo´n and McKearin,
1999; M€uller et al., 2007). In the context of DDR, a number of
chromatin-associated VCP substrates have been identified.
These include Ku70/80 and L3M6BTL1 for DSB repair (Acs
et al., 2011; van denBoomet al., 2016), DDB2 and XPC for nucle-
otide excision repair (Puumalainen et al., 2014), RNA polymerase
II during transcription-coupled DNA repair (Verma et al., 2011),
MCM7 of the CMG replicative helicase complex during DNA
replication termination (Maric et al., 2014; Moreno et al., 2014)
and interstrand cross-link repair (Fullbright et al., 2016), and
CDT1 during DNA replication under normal and DNA-damaging
conditions (Franz et al., 2011; Raman et al., 2011).
The essential role of VCP in chromatin-associated protein
clearance necessary for different DNA-repair mechanisms high-
lights its uniqueness as a general genome caretaker. However,
given the pleiotropic effects of VCP, abolishing its total function
pharmacologically, although showing promising effects in pre-
clinical cancer models, triggers global protein stress (e.g., by in-
hibiting ER-associated degradation [ERAD]) and will likely have
dose-limiting toxicity in patients (Anderson et al., 2015; Her
et al., 2016; Magnaghi et al., 2013). Here, we have characterized
a serendipitously discovered DNA-damage-specific phosphory-
lation event of VCP (Ser784) mediated by members of the DDR
master kinase family, phosphatidylinositol 3-kinase-related ki-
nases (PIKKs). Our data suggest that Ser784 phosphorylation is
a specific enhancer of VCP nuclear functions in DDR and a pre-
dictor of breast cancer response to genotoxic chemotherapies.
RESULTS
Nuclear Antigen Recognized by the pSer137-Pfn1
Antibody Associates with Poor Survival on
Chemotherapy in Breast Cancer
In a prior work, we generated a polyclonal antibody targeting
phospho-Ser137 of the actin-binding factor profilin-1 (Pfn1)
(Shao et al., 2008). Using that antibody to stain a few breast can-
cer samples, we observed positive signals in a subset of cases.
However, both the intensity and the subcellular location of the
signals varied (Figures 1A and S1A). Intrigued by the nuclear
staining because of our interest in nuclear Pfn1 functions (Dia-
mond et al., 2015), we stained a clinically annotated invasive
breast cancer tissue microarray (TMA) (Strategic Partnering to
Evaluate Cancer Signatures [SPECS]) (Cheang et al., 2009;
Graveel et al., 2009) and scored the nuclear signals using the
Allred method (intensity + proportion) (Harvey et al., 1999). Uni-
variate survival analysis revealed an inverse and statistically sig-
nificant correlation between the individual nuclear Allred scores
and clinical outcomes of overall survival (OS) (n = 97, p =
0.0025) and relapse-free survival (RFS) (n = 88, p = 0.0034) by
the log-rank test (Figure 1B). To confirm that result, we next
stained a larger and independent breast cancer TMA (UBC se-
ries) (Bortnik et al., 2016). We observed similar results that high
individual nuclear Allred scores were significantly associated
with a lower RFS (n = 295, p = 0.0034) and trended toward a
lower OS (n = 295, p = 0.071) (Table S1; Figure S1B). To simplify
the analysis, we binarized the nuclear Allred scores into low (0–3)
(n = 191, 65%) versus high (4–8) (n = 104, 35%) subgroups (Table
S2). No significant association was observed between nuclear
Allred scores and patient age at diagnosis, tumor size, nodal sta-
tus, or ER, PR, HER2, or Ki67 status in this dataset. However,
there was a significant association between nuclear Allred
scores and histologic grade (Table S2). Univariate survival ana-
lyses revealed that cases with high Allred scores displayed
significantly lower OS (n = 295, p = 0.0032), RFS (n = 295, p =
0.0003), and breast-cancer-specific survival (BCSS) (n = 293,
p = 0.016) (Figures 1C and S1C). Multivariate analyses, adjusted
for the clinicopathological variables of age, tumor grade and
size, lymphovascular invasion, nodal status, and ER, PR,
HER2, and Ki67 confirmed these results and revealed that the
prognostic value of the nuclear staining is independent of those
variables (Tables S3, S4, and S5). Interestingly, the association
of nuclear scores with patient survival was mainly observed in
the ER-negative subgroup (Figure S1D). There was no detect-
able association between the cytoplasmic staining and survival
outcomes (Figure S1E).
To further investigate the potential clinical relevance of nuclear
staining by the pSer137-Pfn1 antibody, we evaluated its associa-
tion with survival outcomes across themajor immunohistochem-
ical subtypes of breast cancer (Cheang et al., 2008; Goldhirsch
et al., 2011). A significant association between nuclear scores
and survival was only detected in those with triple-negative
breast cancer (TNBC: n = 42; OS, p = 0.0007; BCSS, p =
0.0005; OS-adjusted p = 0.003; BCSS-adjusted p = 0.002) and
basal cases (n = 28; OS, p = 0.02; BCSS, p = 0.007; OS-adjusted
p = 0.10; BCSS-adjusted p = 0.03) (Figures 1D, S2A, and S2B),
although a significant correlation with RFS was also detected
in luminal A cases (n = 151; p = 0.0001; adjusted p = 0.0006) (Fig-
ure S2C). No significant correlation with survival was observed in
luminal B and HER2+ tumors (Figures S2A–S2C).
(E) Univariate Kaplan-Meier analysis of the BCCancer series showing the associations between nuclear staining by the pSer137-Pfn1 antibody and poor survival
outcome (BCSS) of the chemotherapy-treated breast cancer patients. Log-rank and Wilcoxon tests were used. p < 0.05 was considered statistically significant.
Unadjusted p values for the outcome in the chemotherapy-treated group of BCCancer series are displayed.
See also Figures S1–S3 and Tables S1–S9.




Figure 2. pSer784-VCP Is the DNA-Damage-Induced Nuclear Antigen of the pSer137-Pfn1 Antibody
(A) HeLa cells were treated with DMSO, 200 nM of SN38, and 5 mM of etoposide for 6 h, followed by staining using the pSer137-Pfn1 antibody. DAPI was used to
stain DNA.
(B) HeLa cells were treated with DMSO, 200 nM of SN38, and 1 mM of gemcitabine for 16 h, followed by western blot analysis using the pSer137-Pfn1 antibody.
Red arrowhead indicates the DNA-damage-induced ~100-kDa protein.
(C) Nuclear extracts of DMSO- or SN38-treated (200 nM, 16 h) HeLa cells were immunoprecipitated by the pSer137-Pfn1 antibody, followed by SDS-PAGE
analysis and silver staining. The drug-induced protein at ~100 kDa was excised and identified as VCP by mass spectrometry (Held et al., 2013).
(D) Pull-down samples from (C) were analyzed by western blot using a VCP-specific antibody.
(E) HeLa cells were infected with shLuc or two distinct shVCPs for 3 days, treated with 5 mM of etoposide for 6 h, and immunostained using the pSer137-Pfn1
antibody.
(F) HeLa cells were treated with 5 mM of etoposide for 6 h, extracted by the CSK buffer for 5 min, and stained by the pSer137-Pfn1 antibody.
(legend continued on next page)




To investigate these observations according to treatment, we
used the pSer137-Pfn1 antibody to stain a third and substantially
larger breast cancer TMA (BCCancer series) (Cheang et al.,
2006; Liu et al., 2012). We split this dataset into training and vali-
dation sets, each constituting approximately 50% of the total
cases. The distribution of nuclear Allred scores in the training
set of the BCCancer series, compared with the UBC series,
showed a shift to higher levels, possibly because they had
been snap frozen before fixation (Table S6). Thus, we modified
the binarization method to retain a comparable number of cases
in the ‘‘low (0–4)’’ versus ‘‘high (5–8)’’ nuclear score groups and
therebymaximize study power in the validation set. We detected
a statistically significant association between high nuclear
scores and multiple poor prognostic factors, including high
grade, ER negativity, HER2 positivity, non-luminal subtype,
and triple-negative phenotype (Tables S7, S8, and S9).
In the overall dataset, we did not detect significant association
between nuclear scores and survival outcomes (Figure S3A).
However, when dividing the cases into four sub-groups based
on the types of adjuvant therapies given after surgery and per-
forming univariate analysis using BCSS, we found that high nu-
clear scores were significantly associated with worse patient sur-
vival in the chemotherapy-treated group of the training set only
(n = 236; BCSS, p = 0.012; adjusted p = 0.048) (Figure 1E) but
not in the untreated group or in those receiving tamoxifen or
tamoxifen plus chemotherapy (Figure S3B). To assess whether
the failed validation is due to properties specific to the pre-spec-
ified validation set, we randomly repeated the training/validation
set split 500 times. Nuclear scores were found to be significant
(BCSS; within chemotherapy-treated subset; ‘significant’ defined
by lower 95% confidence interval of the hazard ratio >1) on 306
training sets and 115 of the corresponding validation sets. Thus,
the significant results in the training set can be validated by about
40% of the training/validation set splits.
Because the nuclear score appeared to be particularly prog-
nostic for TNBC in the UBC dataset (Figure 1D), we performed
an exploratory analysis to determine whether the combination
of immunohistochemical (IHC) staining and TNBC status would
provide additional information regarding survival in the cohort
of patients treated with chemotherapy. We found that tumors
classified as ‘‘TNBC andwith high nuclear scores’’ had the worst
BCSS compared with the other subgroups (p = 0.028, combined
set; Figure S3C). Thus, our data suggest that the level of nuclear
staining by the pSer137-Pfn1 antibody could potentially predict
breast cancer response to chemotherapy treatments.
VCP Is the DNA-Damage-Induced Nuclear Antigen
Detected by the pSer137-Pfn1 Antibody
Nearly all the chemotherapy drugs used to treat patients in the
BCCancer series are genotoxins (cyclophosphamide, metho-
trexate, 5-fluorouracil, and anthracycline). To investigate
whether there is a link between the nuclear antigen of the
pSer137-Pfn1 antibody and the DNA-damage response, we
treated HeLa and several breast cancer cell lines (BT549,
MDA-MB-231, T47D, and HCC1806) with SN38 (DNA topoisom-
erase I inhibitor) and etoposide (DNA topoisomerase II inhibitor).
Although the untreated cells mainly displayed cytoplasmic reac-
tivity with the pSer137-Pfn1 antibody, as previously described
(Shao and Diamond, 2012), both drugs induced nuclear signals
to various degrees (Figures 2A and S4A). Similar nuclear signals
were induced by genotoxic agents with different mechanisms of
action (Figure S4B) including hydroxyurea (HU), 5-fluorouracil
(5FU), cisplatin, and gemcitabine. Unexpectedly, Pfn1 knock-
down by two different short hairpin RNAs (shRNAs), although
reducing Pfn1 to an undetectable level, showed no effect on eto-
poside-induced nuclear staining (Figures S4C and S4D), sug-
gesting that the nuclear antigen is a different protein.
Because of its clinical importance (Figure 1), we sought to iden-
tify the unknown nuclear antigen. Treating multiple cell lines with
different genotoxic agents reveals an 100-kDa protein recog-
nized by the pSer137-Pfn1 antibody (Figures 2B, S5A, and S5B).
To identify that protein, we subjected the nuclear extracts of un-
treated or SN38-treated HeLa cells to immunoprecipitation using
the pSer137-Pfn1 antibody. Silver staining reveals an 100-kDa
protein specifically present in the SN38-treated sample (Fig-
ure 2C), which was identified by mass spectrometry to be the
AAA+ ATPase VCP. This was confirmed by western blot using a
VCP antibody (Figure 2D). Incubating cell lysates with alkaline
phosphatase before immunoprecipitation by the pSer137-Pfn1
antibody significantly reduced the binding of VCP, confirming
that the reactivity is phosphorylation dependent (Figure S5C).
To confirm that VCP is the nuclear antigen of the pSer137-Pfn1
antibody by immunostaining, we silenced VCP in HeLa cells us-
ing two shRNAs, treated with SN38, and performed immuno-
staining with the pSer137-Pfn1 antibody. Although nuclear sig-
nals are observed in cells infected with a control shRNA, little
to no signals were present in the VCP knockdown cells (Fig-
ure 2E). Notably, detergent extraction of etoposide-treated
HeLa cells before fixation and staining revealed discrete nuclear
structures characteristic of DNA-damage foci (Figure 2F). Thus,
VCP is theDNA-damage-induced nuclear antigen of the pSer137-
Pfn1 antibody.
Ser784 Is the Phosphorylation Site of VCP Recognized by
the pSer137-Pfn1 Antibody
We next sought to identify the VCP epitope that reacts with the
pSer137-Pfn1 antibody. Because there is no obvious similarity be-
tween the antigenic pSer137-Pfn1 peptide (MASHLRRpS137Q)
and the VCP sequence, we took a candidate approach by individ-
uallymutating five serines to alanines in a VCP-GFP construct and
(G) HEK293T cells were transfected with wild-type or mutant VCP-GFP, treated with 200 nM of SN38 for 16hr, and immunoprecipitated using the pSer137-Pfn1
antibody. Pull-down and input samples were analyzed by western blot using a GFP antibody.
(H) Input samples from (A) were analyzed by western blot using the pSer137-Pfn1 or VCP antibodies.
(I) HeLa cells were pre-treated for 30 min with DMSO, 10 mM of caffeine, or 10 mM of KU-55933, followed by 30 min of treatment with 50 mM of etoposide. They
were lysed by RIPA (without SDS), and the soluble and insoluble fractions were analyzed by western blot. pSer784-VCP was detected by the pSer137-Pfn1
antibody.
All data, except (C), were independently confirmed two to three times. Scale bars, 20 mm (A) and (E) and 10 mm (F). See also Figures S4 and S5.




determining the ability of the pSer137-Pfn1 antibody to recognize
the VCP mutants upon DNA damage. The five serines are either
precededby 1–2 basic residues (R/KS) or followed by a glutamate
(SQ) as Ser137 in the antigenic Pfn1 peptide. Upon transfection
into HEK293T cells and SN38 treatment, we used the pSer137-
Pfn1 antibody to immunoprecipitate wild-type versus mutant
VCP-GFP, followed by western blot using a GFP antibody. One
mutant, S784A, although abundantly expressed, was not pulled
down by the pSer137-Pfn1 antibody (Figure 2G). It also does not
react with the antibody directly on western blot (Figure 2H).
Phosphorylation of VCP at Ser784 has been reported to occur in
response to different genotoxic treatments, but the functional sig-
nificance remains completely unknown (Livingstone et al., 2005;
Matsuoka et al., 2007; Stokes et al., 2007). Residing in a pSQ
motif, it is believed to be directly phosphorylated by the PIKK fam-
ilymembers ATM, ATR, or DNA-PKcs, known asmaster DDR reg-
ulators (Blackford and Jackson, 2017). Consistent with that, treat-
ing HeLa cells with caffeine (general ATM/ATR/DNA-PKcs
inhibitor) (Sarkaria et al., 1999) and KU55933 (specific ATM inhib-
itor) (Hickson et al., 2004) significantly inhibits Ser784 phosphory-
lation caused by etoposide (predominantly inducing DSBs, which
activate ATM) (Figure 2I). Interestingly, when cells are lysed with
SDS-free RIPA buffer (radioimmunoprecipitation assay buffer;
1% NP40 and 1% sodium deoxycholate), pSer784-VCP is found
exclusively in the soluble fraction, although a small fraction of total
VCP is detected in the insoluble fraction (Figure 2I).
Generation and Characterization of the Monoclonal
pSer784-VCP Antibody
To further confirm our results and better study pSer784-VCP, we
generated monoclonal antibodies using a synthetic VCP-pep-
tide-harboring pSer784 (GGAGPpS784QGSGGG). One clone
(3E4) was evaluated in parallel to the pSer137-Pfn1 antibody.
3E4 shows superior specificity on western blot and detects the
same 100-kDa protein recognized by the pSer137-Pfn1 antibody
under DNA-damaging conditions (Figure 3A) in an alkaline-phos-
phatase-sensitive manner (Figure 3B). This phospho-protein
was confirmed to be VCP by anti-VCP pull-down under native
and denaturing conditions followed by immunoblotting using
the 3E4 or pSer137-Pfn1 antibodies (Figures 3C and S5D). In a
reciprocal fashion, both antibodies pull down VCP specifically
from genotoxin-treated cells under the native condition (Fig-
ure 3D), and the pSer137-Pfn1 antibody can also do this under
the denaturing condition (Figure S5E). For immunostaining, 3E4
specifically detects nuclei in a DNA-damage-dependent fashion,
which is abolished by VCP knockdown (Figure S5F), and shows
no reactivity in untreated cells (Figure 3E).
Next, we tested whether the DNA-damage-induced nuclear
foci detected by 3E4 and the pSer137-Pfn1 antibody (Figure 2F)
are identical by double labeling of etoposide-treated, pre-ex-
tracted osteosarcoma U2OS cells. We observed complete co-
localization of the nuclear foci recognized by the two antibodies
in all focus-containing cells (Figure 3F). To confirm that they are
DNA-damage foci, we co-stained the cells for well-known DSB
markers (gH2AX) and repair factors (53BP1 and BRCA1). We de-
tected co-localization of pSer784-VCP with nearly all the 53BP1-
positive DNA-damage foci, consistent with the fact that DSB
recruitment of 53BP1 requires VCP (Figure 3G) (Acs et al.,
2011). We also detected significant co-localization between
pSer784-VCP and gH2AX inmore than 50%of the focus-contain-
ing cells (Figure 3H). Interestingly, we detectedminimal co-local-
ization between pSer784-VCP andBRCA1. Fewer cells contained
BRCA1-positive nuclear foci than pSer784-VCP-positive foci,
and of those positive for BRCA1, <10% showed only partial
co-localization with pSer784-VCP (Figure S5G). Thus, pSer784-
VCP is physically present at a subset of DNA-damage sites con-
taining selective DNA repair factors.
To further confirm that the nuclear antigen of the polyclonal
pSer137-Pfn1 antibody in human breast cancer tissues is
pSer784-VCP (Figure 1), we performed parallel staining using the
SPECS TMA. Comparison of nuclear Allred scores of the remain-
ing tissues (n = 69, fewer cases than earlier staining because of
the extensive cutting of the block) revealed highly concordant
staining patterns of 3E4 and the pSer137-Pfn1 antibody (Pearson
correlation coefficient, r2 = 0.9) (Figure 3I). Univariate Kaplan-Me-
ier analysis using further filtered cases containing a sufficient
number of tumor cells revealed that nuclear staining by themono-
clonal 3E4 antibody was significantly correlated with worse RFS
(n = 44, p = 0.0104, log-rank test), in the same trend as nuclear
staining by the polyclonal pSer137-Pfn1 antibody (n = 46, p =
0.1232, log-rank test) (Figure 3J). Despite the limited statistical
power because of the few cases, these data collectively support
that the two antibodies detect a common nuclear antigen,
pSer784-VCP.
Ser784 Phosphorylation Is a Late DNA-Damage-Induced
Event
VCP is well-known for its rapid recruitment to DNA-damage sites
to removeK48-linked polyubiquitinated protein substrates (Meyer
et al., 2012; Vaz et al., 2013). Upon laser-induced DSB in MRC5
fibroblast cells, the biological half-life (t1/2) of VCP-GFP recruit-
ment is reported to be 2 min (Acs et al., 2011). To determine the
kinetics of Ser784 phosphorylation upon DNA damage, we per-
formed laser micro-irradiation in U2OS and BT549 cells and
compared the kinetics of damage site appearance of total VCP
versus pSer784-VCP by immunostaining at different times.We de-
tected VCP at DNA-damage sites (indicated by NBS1, part of the
DSB sensorMRN complex) as early as 1min after laser irradiation
in the U2OS cells and 5 min in the BT549 cells. In contrast,
pSer784-VCP was undetectable until 10–15 min in both cell lines.
Interestingly, diffuse nucleoplasmic pSer784-VCP, although unde-
tectable before laser irradiation, appeared upon DNA damage
and intensified in parallel to pSer784-VCP at the laser-induced
DNAwounds (Figures 4A, S6A, and S6B). Thus, Ser784 phosphor-
ylation occurs as a direct consequence of DNA damage and later
than VCP recruitment to damage sites.
We next chemically induced DSB in HeLa cells using etopo-
side and monitored pSer784-VCP by western blot at different
times. We compared it to well-known DDR signaling events
including auto-phosphorylation of ATM (pSer1981-ATM) and
ATM-dependent phosphorylation of Chk2 (Thr68) and H2AX
(Ser139) (Awasthi et al., 2016). Although these known DDR phos-
phorylation events occur quickly before (pThr68-Chk2 and
pSer1981-ATM) or around 5 min (gH2AX) of treatment and reach
maximal intensities around 30min, pSer784-VCP is detectable af-
ter 20 min and gradually intensifies beyond 120min. No changes




Figure 3. Monoclonal pSer784-VCP Antibody Confirms the Nuclear Antigen of the pSer137-Pfn1 Antibody
(A) HeLa cells treated with DMSO or SN38 (200 nM, 16 h) were analyzed by western blot using the pSer137-Pfn1 or pSer784-VCP antibodies.
(B) HeLa cells treated with etoposide (50 mM, 1 h) were lysed, incubated at 37C for 1 h with or without calf intestinal alkaline phosphatase, and analyzed by
western blot using the pSer137-Pfn1, pSer784-VCP, or pan-VCP antibodies.
(C) HeLa cells treated with DMSO or etoposide (50 mM, 6 h) were subjected to immunoprecipitation by control immunoglobulin G (IgG) or pan-VCP antibody,
followed by western blot using the pSer137-Pfn1, pSer784-VCP, and pan-VCP antibodies.
(D) HeLa cells treated with DMSO or SN38, as in (A), were subjected to immunoprecipitation using the pSer137-Pfn1 or pSer784-VCP antibodies, followed by
western blot using a pan-VCP antibody.
(E) HeLa cells were treated with 200 nM of SN38 for 16 h and immunostained with the pSer784-VCP antibody.
(F) HeLa cells were treated with 50 mM of etoposide for 1 h, followed by double immunostaining using the pSer137-Pfn1 and pSer784-VCP antibodies.
(G and H) U2OS cells were treated with 50 mM of etoposide for 1 h, recovered for 90 min, and detergent-extracted before fixation and double staining by the
pSer137-Pfn1 and 53BP1 antibodies (G) or pSer784-VCP and gH2AX (H) antibodies.
(I) Representative images in the SPECS TMA immunostained in parallel by the pSer137-Pfn1 and pSer784-VCP antibodies.
(J) Univariate Kaplan-Meier analysis of the SPECS TMA stained in (G). Nuclear Allred scores were binarized into low (0–4) versus high (5–8) groups. Two extra
interpretable cases stained by the pSer137-Pfn1 antibody (n = 46) (but not by pSer784-VCP, n = 44) were included in the analysis. p values were based on Log-rank
test.
More than 100 cells per experiment were analyzed for (D)–(F). Data in (A)–(H) have been independently confirmed 2-3 times. Scale bars, 20 mm (E), 4 mm (F–H), and
10 mm (I). See also Figure S5.




in the total protein levels were observed (Figure 4B). Similarly de-
layed pSer784-VCP induction by hydroxyurea (inducing DNA
replication stress and ATR activation) as compared with
pSer345-Chk1 (known ATR substrate) was also observed (Fig-
ure S6C). Thus, Ser784 phosphorylation of VCP is a relatively
late DDR event.
Ser784 Phosphorylation Increases VCP Activity on
Chromatin
Given the essential function of VCP in the turnover of K48-poly-
ubiquitinated proteins, we asked whether Ser784 phosphoryla-
tion has a role in these processes in response to DNA damage.
We used the S784A and S784D mutations to mimic the
Figure 4. Ser784 Phosphorylation Is a Late DNA-Damage-Induced Event
(A) BT549 cells were laser micro-irradiated (Chen et al., 2013) and double labeled at various time points by the pSer784-VCP/NBS1 or VCP/NBS1 antibody pairs
(You et al., 2005). Experiment was independently performed twice with similar results.
(B) HeLa cells were treated continuously with 50 mM of etoposide, lysed by RIPA buffer (no SDS) at the indicated time points, and analyzed for soluble and
insoluble fractions by western blot.
Band intensities were plotted over time for each indicated antibody. Data were independently confirmed three times. Scale bars, 10 mm. See also Figure S6.




unphosphorylated and phosphorylated forms of VCP, respec-
tively. They were introduced into a human VCP-GFP construct
containing silent mutations, which confer resistance to two
different shRNAs (shVCP 1 and 2). Wild-type and mutant VCP-
GFP were stably expressed in HeLa cells at similar levels to
each other and relative to endogenous VCP (Figure 5A). Upon
VCP knockdown in the etoposide-treated GFP control cells,
the level of K48-polyubiquitinated proteins increased signifi-
cantly, both in the RIPA-soluble and insoluble fractions (Figures
5B and S7A). Interestingly, although the increase in the soluble
fractions was similarly rescued by wild-type and mutant VCP-
GFP, the increase in the insoluble fractions was rescued more
effectively by VCP(S784D) and less effectively by VCP(S784A)
compared with VCP(WT) (Figure 5B). To test whether the K48-
polyubiquitin signals in the RIPA-insoluble fractions represent
chromatin-associated proteins, we divided the cells into cyto-
plasm, nucleoplasm, and chromatin fractions. VCP knockdown
increased K48-polyubiquitin in all three fractions, consistent
with its importance in global protein clearance (Figures 5C and
S7B). This was phenocopied by the specific VCP inhibitor
NMS-873 (Magnaghi et al., 2013) (Figure S7C). Interestingly,
the most notable differences between the rescuing activity of
VCP(S784D) (more active) and VCP(S784A) (less active) relative
to VCP(WT) were detected in the chromatin fractions, followed
by subtle differences in the nucleoplasmic fractions. No differ-
ence in the activity of wild-type versusmutant VCPwas detected
in the cytoplasmic fraction (Figures 5C and S7B). Similar results
were also observed in the U2OS cells (Figures S7D and S7E).
To confirm that the observed changes in K48-polyubiquitin
represented VCP substrates, we examined Ku70, the dimeric
partner of Ku80, which is a known chromatin-associated VCP
substrate essential for DSB repair (van den Boom et al., 2016).
Chromatin-associated Ku70 level was increased by VCP knock-
down in etoposide-treated HeLa cells, and that could be
reduced by RNAi-resistant VCP(WT) and VCP(S784D) but not
VCP(S784A) (Figure 5D). Next, we examined the level of HIF1a,
a known soluble nuclear substrate of VCP (Alexandru et al.,
2008). Because of the high turnover rate of HIF1a under normal
conditions, cells were treated with MG-132 for 2 h to reduce
their proteasomal degradation before harvest, as previously
described (Alexandru et al., 2008). Interestingly, the level of
RIPA-soluble HIF1a was significantly decreased by VCP(S784A)
but increased by VCP(S784D) relative to VCP(WT), in clear
contrast to the K48-ubiquitin levels in the insoluble fractions (Fig-
ures 5E and S7F). qRT-PCR showed no changes in the mRNA
level of HIF1a (Figure S7G). These results suggest that Ser784
phosphorylation, induced by DNA damage, preferentially in-
creases nuclear VCP ability to clear chromatin-associated but
not soluble substrates.
Ser784 PhosphorylationDecreases VCPAssociationwith
NPL4/UFD1 and Polyubiquitinated Proteins
To study the regulatory mechanism of Ser784 phosphorylation,
we first examined its effects on the VCP interaction with protein
substrates. We immunoprecipitated total VCP (by a pan-VCP
antibody) or pSer784-VCP (by 3E4) from etoposide or HU-treated
HeLa cell lysates and immunoblotted for co-absorbed K48-poly-
ubiquitinated proteins. Despite the similar amounts of precipi-
tated VCP, 3E4 significantly enriched pSer784-VCP compared
with the pan-VCP antibody. Interestingly, less K48-polyubiqui-
tins were co-adsorbed by 3E4 than by the pan-VCP antibody,
indicating that Ser784 phosphorylation may reduce VCP interac-
tion with substrates (Figure S8A). To better separate pSer784-
VCP from unphosphorylated VCP, we next performed sequential
pull-downs from etoposide-treated HeLa cell lysates to first
deplete pSer784-VCP using 3E4 and subsequently capture the
remaining unphosphorylated VCP by the pan-antibody. We de-
tected significantly less binding of K48-polyubiquitins to
pSer784-VCP than of unphosphorylated VCP. Based on the
levels of VCP in the input and supernatants after each pull-
down, it is evident that Ser784 is phosphorylated at high stoichi-
ometry in response to DNA damage (>50% of total VCP after
overnight etoposide treatment) (Figure 6A). The reduced binding
of K48-polyubiquitins by pSer784-VCP was similarly observed in
etoposide-treated MDA-MB-231 cells (Figure S8B) and was
recapitulated by S784D versus S784A mutants of VCP-FLAG
(Figure 6B). Interestingly, VCP interaction with NPL4 and
UFD1, two core cofactors important for K48-polyubiquitin bind-
ing during chromatin-associated degradation, is similarly
decreased by Ser784 phosphorylation (Figures 6B and S8B).
Next, we examined the effect of Ser784 phosphorylation on
VCP association with chromatin. S784A mutation significantly
increased VCP level in RIPA-insoluble, chromatin-enriched frac-
tions of etoposide-treated VCP knockdown and rescue HeLa
cells. Conversely, S784D caused a decrease of RIPA-insoluble
VCP (Figures 6C and S7H). Consistent with that, subcellular frac-
tionation showed more chromatin-associated VCP(S784A) than
VCP(WT) and VCP(S784D) did, despite their similar nucleo-
plasmic levels (Figures 6D and S7I). Similar results were also
observed in etoposide-treated MDA-MB-231 cells expressing
wild-type and mutant VCP-FLAG (Figures S8C and S8D). Thus,
the increased chromatin-selective activity of pSer784-VCP ap-
pears to correlate with decreased association with NPL4/UFD1
and polyubiquitinated substrates.
Ser784 Phosphorylation of VCP Is Important for DNA-
Damage Response and Cell Survival upon Genotoxic
Stress
To determine the functional significance of Ser784 phosphoryla-
tion for DNA-damage response, we performed VCP knock-
down and rescue in etoposide-treated HeLa cells, as described
in Figure 5. First, we examined DDR signaling by quantifying
the phosphorylation events of the PIKK kinases. Using an anti-
body against the consensus pS/TQ motif and two well-known
ATM substrates pSer343-NBS1 and pThr68-Chk2 functionally
important for DSB repair and cell cycle checkpoint, we de-
tected within RIPA-soluble fractions a significant decrease in
PIKK signaling upon VCP knockdown (in GFP control cells),
which was fully rescued by wild-type VCP (Figure 7A). Chemi-
cal inhibition of VCP by NMS-873 similarly decreased PIKK
signaling (Figure S9A). Interestingly, although VCP(S784D)
showed similar rescuing activity as VCP(WT) did, VCP(S784A)
was nearly inactive (Figure 7A). Similar results were observed
in HU-treated HeLa cells (Figure S9B). In contrast, the increase
in endoplasmic reticulum stress, indicated by Bip1 and CHOP
induction, as a result of VCP knockdown can be fully rescued




by both wild-type and mutant VCP (Figure 7A), consistent with
their similar abilities to clear cytosolic polyubiquitinated pro-
teins (Figure 5B).
We next tested whether Ser784 phosphorylation of VCP regu-
lates PIKK signaling by affecting its chromatin binding upon
DNA damage. Unexpectedly, in the etoposide or HU-treated
VCP knockdown HeLa cells rescued by VCP(S784A), we de-
tected more chromatin-associated ATM and ATR, respectively,
than in the cells expressing VCP(WT) and VCP(S784D) (Figures
S9C and S9D). Higher levels of phosphorylated ATM substrates,
pSer343-NBS1 and gH2AX, are found in chromatin fractions of
the VCP(S784A) cells (Figure S9C). This is in contrast to the
reduced pSer1981-ATM and pSer343-NBS1 in the soluble nucleo-
plasm of VCP(S784A) cells compared with those expressing
VCP(WT) and VCP(S784D) (Figure S9C). We could not detect
pSer1981-ATM in the chromatin fractions, possibly because
only a small fraction of total ATM is retained on chromatin after
fractionation (Figure S9E). Nonetheless, immunostaining re-
vealed more VCP(S784A)-rescued cells containing pSer1981-
ATM-positive DNA-damage foci (Figure S9F). Thus, Ser784 phos-
phorylation of VCP appears to differentially affect PIKK signaling
within DNA-damage sites on chromatin versus in the soluble
nucleoplasm.
Next, we investigated whether Ser784 phosphorylation of
VCP affects cell survival after DNA damage. Consistent with
its essentiality, VCP knockdown caused cell death within 5–
7 days without genotoxic stress, and that could be rescued
by VCP, regardless of Ser784 mutations (Figures S10A and
S10B). This enabled us to use the knockdown and rescue
strategy (as in Figure 5) to ‘‘replace’’ endogenous VCP with
RNAi-resistant wild-type and mutant VCP and specifically to
study the effect of Ser784 phosphorylation on DNA-damage-
induced cell death. Treating the resultant U2OS cells with a
panel of genotoxic agents (5FU, HU, cisplatin, SN38,
and PARP inhibitors olaparib and niraparib) revealed that cells
expressing VCP(S784A) survive significantly less than those
expressing VCP(WT) and VCP(S784D) (Figures 7B and
S10C). Similar effects were also observed in HeLa cells
(Figure S10D).
Last, we tested whether the pro-survival effect of pSer784-
VCP upon genotoxic stress correlates with increased DNA-
damage repair. We treated the VCP knockdown and rescue
U2OS cells with etoposide and HU and used the comet assay
to quantify single- and double-stranded DNA breaks under
alkaline conditions. In response to both drugs, significantly
fewer DNA breaks were detected in VCP(S784D) than
Figure 5. Ser784 Phosphorylation Increases
VCP Activity Specifically in the Nucleus
(A) HeLa cells stably expressing GFP or RNAi-
resistant VCP-GFP (WT or mutants) were infected
with shLuc or shVCP1 and 2 combined. Cells were
analyzed 4 days later by western blot using anti-
bodies against VCP (detecting both endogenous
VCP and exogenous VCP-GFP) or actin.
(B) Cells in (A) were treated with 50 mM of etopo-
side for 30 min, recovered for 1 h, lysed by RIPA
buffer (no SDS), and analyzed for soluble and
insoluble fractions by western blot using a K48-
linkage-specific polyubiquitin antibody controlled
by histone H3 or GAPDH.
(C) Etoposide-treated HeLa cells, as in (B), were
subjected to subcellular fractionation (Me´ndez
and Stillman, 2000), followed by western blot
analysis of the resulting cytoplasmic, nucleo-
plasmic, and chromatin fractions using the K48-
ubiquitin antibody controlled by GAPDH, actin,
and histone H3. Densitometry was performed to
quantify K48-polyubiquitin levels in (B) and (C),
which were subsequently normalized over the in-
ternal controls.
(D) Chromatin fractions from (C) were analyzed by
western blot for Ku70.
(E) VCP knockdown and rescue HeLa cells were
treated with 50 mM of etoposide for 30 min,
recovered for 2 h in the presence of 20 mM of MG-
132, and lysed with RIPA buffer. Soluble and
insoluble fractions were analyzed by western blot
for HIF1a and K48-ubiquitin, with tubulin and H3
as loading controls.
See also Figure S7.




detected in VCP(WT) and VCP(S784A) cells (Figure 7C).
Collectively, these results demonstrate the functional impor-
tance of VCP phosphorylation at Ser784 for DNA-damage
repair, global PIKK-dependent DDR signaling, and cell sur-
vival, further supporting the idea that pSer784-VCP may be
used to predict the outcome of chemotherapy-treated patients
with breast cancer.
DISCUSSION
In this study, we discovered that Ser784 phosphorylation is
an important regulatory event of VCP, specifically for its nu-
clear DDR functions. This work was motivated by the seren-
dipitous finding that an unknown nuclear phospho-protein,
cross-reacting with the pSer137-Pfn1 antibody, significantly
correlated with poor survival for breast cancer patients
receiving genotoxic chemotherapies. This unexpected, yet
clinically important, finding led us to the identification of
pSer784-VCP as the underlying nuclear antigen and our sub-
sequent investigation that revealed its functional importance
for DDR.
Although several phosphorylation events of VCP have been
reported, Ser784 is the only DNA-damage-induced phospho-
site unbiasedly and independently detected by different
studies. It was first described by Livingstone et al. (2005) in a
similarly serendipitous fashion, using a cross-reacting phos-
pho-Chk2 antibody, which detected pSer784-VCP at DNA-dam-
age foci in response to various genotoxic treatments. Subse-
quently, two unbiased proteomic studies independently
Figure 6. Ser784 Phosphorylation Decreases
VCP Association with Chromatin and Polyu-
biquitinated Proteins
(A) HeLa cells were treated with 5 mM of etoposide
overnight, lysed with SDS-free RIPA, and immu-
noprecipitated first with the pSer784-VCP antibody;
the supernatant of which was subsequently
immunoprecipitated by the VCP pan-antibody.
(B) MDA-MB-231 cells stably expressing YFP-
FLAG or VCP-FLAG (S784A versus S784D) were
treated with 200 nM of SN38 overnight, and
nucleoplasmic fractions were immunoprecipitated
by the anti-FLAG antibody.
(C) HeLa cells expressing RNAi-resistant VCP-GFP
were infected with combined shVCP1 and 2,
treated with 50 mM of etoposide for 45 min,
recovered for 1 h, lysed with SDS-free RIPA buffer,
and analyzed by western blot.
(D) Similarly treated HeLa cells as in (C) were
fractionated and analyzed by western blot using
nucleoplasm and chromatin fractions. Data were
independently confirmed two to three times.
See also Figures S7 and S8.
confirmed Ser784 phosphorylation (the
only detectable phospho-site on VCP) in
response to IR and UV (Matsuoka et al.,
2007; Stokes et al., 2007). However, its
physiological significance remained un-
known before our study.
Here, more than a decade later, we provide clinical and mech-
anistic evidence for the functional importance of Ser784 phos-
phorylation in DDR. Clinically, our data suggest that the level of
nuclear pSer784-VCP, recognized by the cross-reacting
pSer137-Pfn1 antibody, is associated with poor outcome among
patients with breast cancer who received genotoxic therapies
(cyclophosphamide, methotrexate, 5FU, and anthracyclines)
but not among those receiving the ER-antagonist tamoxifen or
no adjuvant systemic therapy at all. Notably, pSer784-VCP level
used for our analysis is in the surgical tumor samples taken
before the adjuvant treatments. In other words, it is the baseline
pSer784-VCP level induced by endogenous DNA damage that
predicts the survival for patients subsequently treated with adju-
vant genotoxic chemotherapy. However, discrepancy is
conceivable between the ‘‘baseline’’ and the ‘‘drug-induced’’
pSer784-VCP levels. For instance, certain tumors containing
low levels of endogenous DNA damage would present low base-
line pSer784-VCP levels, but may phosphorylate Ser784 to high
levels upon exogenous drug treatments. Thus, although valid,
our data likely underestimates the true chemo-predictive ability
of pSer784-VCP. Future studies can better assess this by treating
patients neoadjuvantly (before surgery) with genotoxic agents
and staining biopsy samples for ‘‘induced’’ pSer784-VCP to
correlate with short-term neoadjuvant tumor response and
long-term survival during or after adjuvant treatment. Moreover,
because Ser784 phosphorylation occurs in cell lines derived from
various tissues (Figures S4A and S4B) (Livingstone et al., 2005;
Matsuoka et al., 2007; Stokes et al., 2007) and protects them
from a wide range of DNA-damaging agents, including PARP




inhibitors (Figure 7B), it is likely a general predictor of genotoxic
chemotherapy susceptibility for a broad range of cancer types.
Although our data suggest that tumors containing low levels of
‘‘induced’’ pSer784-VCP can be treated effectively by chemo-
therapy, they also implicate those containing high levels of
pSer784-VCP as perhaps being sensitized by PIKK inhibitors,
such as those against ATM and ATR. Multiple ATM and ATR in-
hibitors have entered clinical trials for different cancer types as
monotherapies or radio- and chemo-sensitizers, supported by
strong preclinical data (Brandsma et al., 2017; Durant et al.,
2018; Weber and Ryan, 2015). However, because both kinases
phosphorylate hundreds of proteins upon DNA damage, identi-
fying the ‘‘driver’’ substrates with the functional capability of
determining cell fate is important. VCP may be one such candi-
date because it is phosphorylated by both kinases and protects
genome stability against a broad range of insults (Meyer et al.,
2012; Meyer and Weihl, 2014; Ramadan et al., 2017; Vaz et al.,
2013) (Figures 7B, S10C, and S10D). Nevertheless, inhibiting
VCP function pharmacologically triggers global proteostatic
stress throughout the cell and will likely cause dose-limiting
toxicity when used in patients (Anderson et al., 2015; Her et al.,
2016; Magnaghi et al., 2013). Instead, our work shows that nu-
clear, but not cytoplasmic, VCP can be selectively activated by
ATM- and ATR-mediated Ser784 phosphorylation. Thus,
pSer784-VCP levels may be an indicator of cellular reliance on
ATM and ATR activities, and inhibiting ATM and ATR in
Figure 7. Ser784 Phosphorylation of VCP Is
Important for DNA-Damage Response and
Cell Survival upon Genotoxic Stress
(A) shLuc- or shVCP-infected stable HeLa cells
were treated with 50 mM of etoposide for 30 min,
recovered for 1 h, lysed by RIPA, and analyzed by
western blot.
(B) shLuc- or shVCP-infected stable U2OS cells
were treated with vehicle or different drugs for 16
h, and subjected to colony formation assays for
10–14 days (Guzma´n et al., 2014). Relative effects
represent normalized drug/vehicle percentages.
Shown are means ± SEM of three technical repli-
cates of single biological experiments for each
drug. p Values were based on unpaired t tests
(S784A versus WT or S784D).
(C) shVCP2-infected U2OS stable cells were
treated with 25 mM of etoposide for 30 min fol-
lowed by 1 h of recovery or 1mMHU for 16 h. Cells
were subjected to the comet assay under the
alkaline condition, and tail DNA percentages were
calculated (Gyori et al., 2014). Shown are single
biological experiments with 150–300 cells
analyzed per condition. Error bars represent SEM.
p Values were based on unpaired t tests. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001. Results in
(B) and (C) were confirmed by three biological
replicates.
(D) Working model of enhanced substrate extrac-
tion from chromatin by VCP upon DNA-damage-
induced Ser784 phosphorylation. In this model,
Ser784 phosphorylation is a relatively late DDR
event that occurs either in the nucleoplasm or on
chromatin after VCP binding to polyubiquitinated
substrates (both scenarios are depicted). Ser784
phosphorylation does not abolish chromatin
recruitment of VCP but promotes substrate
extraction and subsequent degradation at least
partially because of its weakened interaction
with cofactors NPL4 and UFD1, which directly
bind substrates. Dissociated pSer784-VCP can
regain access to chromatin and extract more
substrates.
Scale bars, 40 mm. See also Figures S9 and S10.




pSer784-VCP-high tumorsmay be an effective chemo-sensitizing
approach worth testing in the future.
As a substrate of PIKKs, VCP is reciprocally important for PIKK
activation upon DNA damage (Figures 7A and S9B). Interest-
ingly, this requires Ser784 phosphorylation in a context-depen-
dent manner. Preventing Ser784 phosphorylation, although
decreasing phosphorylation of soluble substrates of ATM/ATR,
actually increases ATM/ATR presence and activity on chromatin
(Figures S9C–S9F). Although somewhat surprising, this finding
highlights the complexity of the regulatory mechanisms for
PIKK signaling and suggests that the chromatin-associated
and soluble signaling events can be differentially regulated.
Ser784 phosphorylation may increase the ability of VCP to mobi-
lize chromatin-activated PIKKs or increase their dynamic ex-
change between chromatin and nucleoplasm to more efficiently
phosphorylate soluble substrates. Additionally, by increasing the
ability of VCP to extract chromatin-associated substrates, such
as KRAB-associated protein 1 (KAP1), Ser784 phosphorylation
may promote the global chromatin relaxation necessary for fully
activating ATM beyond the DNA-damage sites (Kuo et al., 2016;
Wu et al., 2011; Ziv et al., 2006). As for ATR, because it is
frequently activated at single and double DNA junctions during
ATM-dependent DSB resections (Shiotani and Zou, 2009; You
et al., 2009), similar regulatory mechanisms by pSer784-VCP
may exist as well.
Our finding that Ser784 phosphorylation specifically increases
VCP activity on chromatin is somewhat surprising, given that
pSer784-VCP interacts with NPL4/UFD1 with lower affinity (Fig-
ures 6B and S8B). NPL4 and UFD1 are the core cofactors of
VCP that directly bind polyubiquitins on many substrates and
are important for chromatin-associated degradation (Meyer
et al., 2012; Meyer and Weihl, 2014; Vaz et al., 2013). Thus, a
reduced interactionwithNPL4/UFD1would be expected to inhibit
VCP access to its substrates and can logically explain the higher
level of HIF1a in cells expressing the phosphomimetic
VCP(S784D) (Figure 5E). However, the increased activity of
pSer784-VCP toward its chromatin-associated substrates seems
counter-intuitive and mechanistically puzzling. In addition to the
reduced interaction with NPL4/UFD1 and polyubiquitinated sub-
strates, pSer784-VCP also seems to associatewith chromatin with
less affinity, biochemically speaking (Figures 6C and 6D), but is
readily detected at DNA-damage sites by immunostaining (Fig-
ures 3G, 3H, and 4A). Based onall thesedata, wepropose awork-
ing model that Ser784 phosphorylation may promote chromatin
protein extraction by accelerating VCP dissociation from chro-
matin and NPL4/UFD1 to facilitate substrate release during the
late stage of extraction (Figure 7D). Indeed, phosphorylation trig-
gers chromatin release of several known DDR factors, including
KAP1 (Goodarzi et al., 2008), Rad9 (Furuya et al., 2010), and
Chk1 (Smits et al., 2006), each for a distinct purpose. However,
the opposing effects of Ser784 phosphorylation on soluble (e.g.,
HIF1a) versus chromatin substrates of VCP and the clear pres-
ence of pSer784-VCP at DNA-damage sites suggest the involve-
ment of additional cofactors that enable chromatin access of
pSer784-VCP independently of NPL4/UFD1. An example of such
cofactors during DNA-replication stress is DVC1, which delivers
VCP to stalled replication forks to extract trans-lesion DNA poly-
merase (Davis et al., 2012; Mosbech et al., 2012).
The fact that Ser784 phosphorylation, within the C-terminal tail
of VCP (763–806 amino acids [aa]), weakens the interaction with
NPL4/UFD1 at the N-terminal domain suggests long-range
conformational changes. Indeed, inter-domain communication
is well-known for VCP and crucial for its ATP-dependent segre-
gase activity (Tang and Xia, 2016). For example, nucleotide bind-
ing and hydrolysis in the central ATPase domains alter the rela-
tive position of the N-terminal domain, which presumably
produces the mechanical force during protein extraction (Bane-
rjee et al., 2016; Schuller et al., 2016; Tang et al., 2010).
Conversely, conformation of theN-terminal domain and its occu-
pancy by cofactors influence the enzymatic activity of the
ATPase domains (Meyer et al., 1998; Niwa et al., 2012; Zhang
et al., 2015). The C-terminal tail of VCP is poorly understood,
both structurally and functionally. However, it can directly
interact with several proteins, including PNGase, PLAA/UFD3,
and UFD2, although none has been linked to DDR (Li et al.,
2006; Qiu et al., 2010; Rumpf and Jentsch, 2006; Zhao et al.,
2007). Interestingly, Tyr806 phosphorylation occurs in the C-ter-
minal tail in response to T-cell receptor activation and abolishes
the interaction with PNGase and PLAA (Egerton et al., 1992; Qiu
et al., 2010; Zhao et al., 2007). These studies raise the possibility
that Ser784 phosphorylation, in response to DNA damage, may
alter the local interaction of VCP with certain C-terminally asso-
ciated proteins and, in turn, cause long-range a conformational
change to weaken the binding of NPL4/UFD1 at the N terminus.
In summary, we have provided clinical and experimental evi-
dence that pSer784-VCP is a cancer prognostic biomarker that
can potentially predict chemotherapy response because of its
importance for DDR. However, regulatory mechanisms of
Ser784 phosphorylation remain partially understood and will be
further examined in the future. These include a validation and
mechanistic investigation of the different effects of Ser784 phos-
phorylation on VCP substrates and PIKK signaling within soluble
nucleoplasm versus on chromatin, as well as cell cycle analysis
to confirm the role of Ser784 phosphorylation in PIKK-dependent
checkpoint activation (which could not be performed because of
the COVID-19 pandemic). Future studies should also investigate
the changes in VCP conformation and its interactome upon
Ser784 phosphorylation to mechanistically explain its functional
importance for DDR. Last, proper validation of the prognostic
value of pSer784-VCP using the monoclonal antibody will be
crucial for translating it into a clinically useful biomarker.
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REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit polyclonal anti-pSer137-Pfn1 Previous Paper (Shao et al., 2008) N/A
Rabbit monoclonal anti-pSer784-VCP, clone (3E4) This Paper N/A
Rabbit monoclonal anti-GFP Cell Signaling Technology Cat#2956; RRID: AB_1196615
Mouse monoclonal anti-VCP Santa Cruz Cat#sc-57492; RRID: AB_793927
Cat#sc-136273; RRID: AB_2214651
Mouse monoclonal anti-actin Santa Cruz Cat#sc-47778; RRID: AB_626632
Mouse monoclonal anti-GAPDH Santa Cruz Cat#sc-365062; RRID: AB_10847862
Rabbit monoclonal anti-Histone H3 Cell Signaling Technology Cat#4499; RRID: AB_10544537
Rabbit monoclonal anti-gH2AX Cell Signaling Technology Cat#9718; RRID: AB_2118009
Mouse monoclonal anti-Ku70 Santa Cruz Cat#sc-17789; RRID: AB_628454
Mouse monoclonal anti-ATM Santa Cruz Cat#sc-377293
Rabbit monoclonal anti-pSer1981-ATM Cell Signaling Technology Cat#5883; RRID: AB_10835213
Rabbit monoclonal anti-pSer428-ATR Cell Signaling Technology Cat#2853; RRID: AB_2290281
Mouse monoclonal anti-Chk2 Cell Signaling Technology Cat#3440; RRID: AB_2229490
Rabbit monoclonal anti-pThr68-Chk2 Cell Signaling Technology Cat#2197; RRID: AB_2080501
Rabbit monoclonal anti-pSer345-Chk1 Cell Signaling Technology Cat#2348; RRID: AB_331212
Rabbit monoclonal anti-NBS1 Cell Signaling Technology Cat#14956; RRID: AB_2798660
Rabbit monoclonal anti-pSer343-NBS1 Cell Signaling Technology Cat#3001; RRID: AB_10829154
Rabbit polyclonal anti-K48-ubiquitin Cell Signaling Technology Cat#4289; RRID: AB_10557239
Rat monoclonal anti-FLAG tag BioLegend Cat#637301; RRID: AB_1134266
Rabbit polyclonal anti-NPL4 Bethyl Laboratories Cat#A304-102A; RRID: AB_2621351
Rabbit polyclonal anti-UFD1 Bethyl Laboratories Cat#A301-875A; RRID: AB_1309801
Mouse monoclonal anti-CHOP Cell Signaling Technology Cat#2895; RRID: AB_2089254
Rabbit monoclonal anti-BiP Cell Signaling Technology Cat#3177; RRID: AB_2119845
Rabbit monoclonal anti-phospho-ATM/ATR
substrate motif
Cell Signaling Technology Cat# 6966, RRID: AB_10949894
Rabbit monoclonal anti-Pfn1 Cell Signaling Technology Cat#3246; RRID: AB_2163185
Mouse monoclonal anti-BRCA1 Santa Cruz Cat#sc-6954; RRID: AB_626761
Mouse monoclonal Anti-Human 53BP1(Clone19) BD Biosciences Cat#612522; RRID: AB_2206766
Mouse anti-tubulin Sigma Cat#T9026; RRID: AB_477593
Rabbit polyclonal anti-PELP1 Bethyl Laboratories Cat# A300-180A
Rabbit monoclonal anti-ATR Cell Signaling Technology Cat# 13934; RRID: AB_2798347
Mouse monoclonal anti-HIF1 alpha Cell Signaling Technology Cat# 79233; RRID: AB_2799924
Rabbit monoclonal anti-K48-linked polyubiquitin Cell Signaling Technology Cat# 8081; RRID: AB_10859893
Mouse monoclonal anti-pSer1981-ATM Rockland Cat# 200-301-400; RRID: AB_217868
Bacterial and Virus Strains
Stbl2 competent cells Thermo Fisher Cat#: 10268019
Stbl3 competent cells Thermo Fisher Cat#: C737303
DH5 alpha competent cells Thermo Fisher Cat#: 18258012
XL10-Gold ultracompetent cells Agilent Cat#: 200314
Chemicals, Peptides, and Recombinant Proteins
Etoposide Selleckchem Cat#S1225; CAS:33419-42-0
KU55933 Selleckchem Cat#S1092; CAS:587871-26-9
(Continued on next page)
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Niraparib Selleckchem Cat#S7625; CAS:038915-73-9
Olaparib Selleckchem Cat#S1060; CAS:763113-22-0
Cisplatin Selleckchem Cat#S1166; CAS:15663-27-1
Gemcitabine Selleckchem Cat#S1714; CAS:95058-81-4
Hydroxyurea Sigma Cat#H8627; CAS:27-07-1
5-Fluoracil Sigma Cat#F6627; CAS:51-21-8
SN38 Sigma Cat#H1065; CAS:86639-52-3
NMS-873 Selleckchem Cat#S7285; CAS:1418013-75-8
MG-132 Selleckchem Cat# S2619; CAS:133407-82-6
Critical Commercial Assays
ImmPACT DAB kit Vectorlabs Cat#SK-4105
Single Cell Gel Electrophoresis Assay Trevigen Cat#4250-050-K
Experimental Models: Cell Lines
Human: T47D ATCC HTB-133
Human: HCC1806 ATCC CRL-2335
Human: HeLa ATCC CCL-2
Human: HEK293T ATCC CRL-11268
Human: U2OS ATCC HTB-96
Human: MDA-MB-231 ATCC HTB-26
Human: BT549 ATCC HTB-122
Oligonucleotides
shLuc: ATATCCGAGTGTAGTAAACATT This Paper N/A
shPfn1#1: GTGGTTTGATCAACAAGAA (Diamond et al., 2015) N/A
shPfn1#2: TACGTGAATGGGCTGACACTT (Diamond et al., 2015) N/A
The primers for VCP S784A: sense
TGGAGCTGGCCCCGCTCAGGGCAGTGGA
This Paper N/A
The primer for VCP S784D: sense
TGGAGCTGGCCCCGATCAGGGCAGTGGA
This Paper N/A
The primers for VCP S784A: antisense
TCCACTGCCCTGAGCGGGGCCAGCTCCA
This Paper N/A
The primer for VCP S784D: antisense
TCCACTGCCCTGATCGGGGCCAGCTCCA
This Paper N/A
shVCP#1: CCTGATGTGAAGTACGGCAAA This Paper N/A
shVCP#2: AGGGAGGTAGATATTGGAATT This Paper N/A
Recombinant DNA
VCP(WT)-GFP (shVCP#1,Resistant) This Paper N/A
VCP(WT)-GFP (shVCP#2,Resistant) This Paper N/A
VCP(WT)-EGFP Addgene Cat#23971; RRID: Addgene_23971
pEGFP-C1 Clontech (discontinued) https://www.addgene.org/vector-
database/2487/
pFLRu-NYFP-FH Feng et al., 2010 N/A
VCP(WT)-FLAG This Paper N/A
VCP(S784A)-EGFP This Paper N/A
VCP(S784D)-EGFP This Paper N/A
VCP(S326A)-EGFP This paper N/A
VCP(S652A)-EGFP This paper N/A
VCP(S746A,S748A)-EGFP This paper N/A
pFLRu-FH vector (Feng et al., 2010) N/A
VCP(S664A)-EGFP This paper N/A
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Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jieya
Shao (shao.j@wustl.edu)
Materials Availability
Reagents generated in this study will be made available on request with a completed Materials Transfer Agreement.
Data and Code Availability
This study did not generate any unique datasets or code.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
All cell lines were originally purchased from ATCC. HeLa, HEK293T, and U2OS cells were grown in high glucose DMEM supple-
mented with 5% or 10% fetal bovine serum and 50 mg/mL gentamicin. MDA-MB-231, BT549, T47D, and HCC1806 were grown in
RPMI 1640 containing 5% or 10% fetal bovine serum (FBS) with gentamicin and supplements (50 mg/mL gentamycin, 1mM sodium
pyruvate, 10 mM HEPES and glucose to 4.5 g/L). Transient transfection was performed using Fugene HD or Lipofectamine 2000.
Lentiviruses were generated using HEK293T cells as previously described (Diamond et al., 2015). Stable HeLa and U2OS cells ex-
pressing GFP or VCP-GFP (WT and mutants) were generated by transfection, 2 weeks of G418 (0.8mg/ml) selection, and FACS. Sta-




Custom-made polyclonal rabbit pSer137-Pfn1 antibody was generated previously (Shao et al., 2008). The monoclonal pSer784-VCP
antibody was custom generated byGenscript. Briefly, a peptide (GGAGPpSQGSGGGTGC, C-terminal cysteine was added) contain-
ing phospho-Ser784 of VCP was synthesized, KLH conjugated, used to immunize BALB/c mice. Two rounds of cell fusions were per-
formed followed by screening of 20,000 clones by indirect ELISA (using the antigenic phospho-peptide and the control peptide
without the phosphate on Ser784). Five positive clones were selected for subcloning and supernatants of each clone were tested
for pSer784-VCP specificity by western blot. One clone (3E4) was selected, expanded, and grown in serum-free hydridoma-SFMme-
dia (GIBCO, cat # 12045-076) followed by purification using the HiTrap protein G column according to manufacturer’s protocol (GE
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
VCP(S784A)-FLAG This paper N/A
VCP(S784D)-FLAG This paper N/A
VCP(S784A)-GFP (shVCP#1,Resistant) This paper N/A
VCP(S784A)-GFP (shVCP#2,Resistant) This paper N/A
VCP(S784D)-GFP (shVCP#1,Resistant) This paper N/A
VCP(S784D)-GFP (shVCP#2, Resistant) This paper N/A
Software and Algorithms
R software The R foundation N/A
SPSS version 23 IBM corporation N/A
ImageJ with the OpenComet plugin (Gyori et al., 2014) http://www.cometbio.org/index.html
GraphPad Prism 7 GraphPad software N/A
Cellsens software Olympus Lifescience N/A
Other
SignalStain Boost IHC Detection Reagent, mouse Cell Signaling Technology Cat#: 8125
SignalStain Boost IHC Detection Reagent, rabbit Cell Signaling Technology Cat#: 8114
RIPA lysis buffer Cell Signaling Technology Cat#: 9806
HiTrap protein G column GE healthcare cat#: 17040403
Mouse monoclonal anti-FLAG M2 affinity gel Sigma Cat#: A2220




healthcare, cat # 17040403). Commercial antibodies used for western blot includeGFP (CST, #2956), VCP (Santa Cruz, sc-57492 and
sc-136273), actin (Santa Cruz, sc-47778), GAPDH (Santa Cruz, sc-365062), histone H3 (CST, #4499), tubulin (Sigma, T9026), PELP1
(Bethyl, #A300-180A), gH2AX (CST, #9718), Ku70 (Santa Cruz, sc-17789), ATM (Santa Cruz, sc-377293), pSer1981-ATM (CST, #5883;
Rockland, #200-301-400), pSer428-ATR (CST, #2853), ATR (CST, #13934), Chk2 (CST, #3440), pThr68-Chk2 (CST, #2197), pSer345-
Chk1 (CST, #2348), NBS1 (CST, #14956), pSer343-NBS1 (CST, #3011), K48-ubiquitin (CST, #4289; CST, #8081), FLAG tag
(BioLegend, #637301), NPL4 (Bethyl, #A304-102A), UFD1 (Bethyl, #A301-875A), CHOP (CST, #2895), BiP (CST, #3177), phos-
pho-ATM/ATR substrate motif (CST, #6966), Pfn1 (CST, #3246), HIF1a (CST, #79233). Antibodies for immunofluorescence staining
include BRCA1 (Santa Cruz, sc-6954), 53BP1 (BD Biosciences, #612522), gH2AX (CST, #9718), VCP (Santa Cruz, sc-57492),
pSer1981-ATM (Rockland, #200-301-400)custom-made pSer137-Pfn1, pSer784-VCP, and NBS1 as previously described (You et al.,
2005). Commercial antibodies for immunoprecipitation include VCP (sc-57492) and anti-FLAG M2 affinity gel (Sigma, A2220).
Drugs
Drugs were purchased from Selleckchem (NMS-873, S7285; Etoposide, S1225; KU55933, S1092; Niraparib, S7625; Olaparib,
S1060; Cisplatin, S1166, Gemcitabine, S1714, MG-132, S2619), Sigma (Hydroxyurea, H8627; 5-Fluoracil, F6627; SN38, H1065).
DNA and shRNA constructs
Human VCP(wt)-GFP in the pEGFP-N1 vector was purchased from Addgene (#23971) (Tresse et al., 2010). VCP was digested out of
pEGFP-N1 with BglII (50) and Age I (30) and cloned into the same sites in the lentiviral pFLRu-FH vector to generate VCP(wt)-FLAG-
6His (Feng et al., 2010). S784A and S784D were introduced using QuickChange site-directed mutagenesis. S784A sense primer:
TGGAGCTGGCCCCGCTCAGGGCAGTGGA; antisense primer: TCCACTGCCCTGAGCGGGGCCAGCTCCA. S784D sense primer:
TGGAGCTGGCCCCGATCAGGGCAGTGGA; antisense primer: TCCACTGCCCTGATCGGGGCCAGCTCCA. Two human VCP-spe-
cific shRNAs in the pLKO.1 vector were purchased from the RNAi consortium at the Genome Institute at Washington University:
CCTGATGTGAAGTACGGCAAA (#1) and AGGGAGGTAGATATTGGAATT (#2). To confer shRNA resistance, multiple synonymous
mutations were introduced within the target sequences of VCP by Genewiz: CCAGACGTCAAATATGGTAAG (#1) and CGCGAAGTT
GAGATAGGAATT (#2). Two human Pfn1-specific shRNAs were described previously (Diamond et al., 2015).
Immunohistochemistry staining and scoring
Formalin-fixed and paraffin-embedded human breast cancer TMAs were purchased from US Biomax or custom generated as
described previously (Cheang et al., 2008, 2009; Graveel et al., 2009; Liu et al., 2012). The UBC series refers to patients diagnosed
with invasive breast cancer at the University of British Columbia hospitals between 1989 and 2002 as previously described (Bortnik
et al., 2016). The BCCancer series was derived from 4543 samples from patients diagnosed with invasive breast cancer in the prov-
ince of British Columbia in the period January 1986–September 1992. These cases are linked to well-annotated clinical data
regarding age, staging, histology, pathological factors, long-term follow-up and information on adjuvant systemic therapy as previ-
ously published (Cheang et al., 2006; Liu et al., 2012). Tissues were subjected to standard rehydration and antigen retrieval by boiling
in 10mM Tris-HCl, pH 9.0 for 10min. Following quenching with 3% hydrogen peroxide for 10min, they were washed with TBS/0.1%
Tween 20 (TBST), and blocked for 1hr at room temperature with 5%normal goat serum and 4%BSA in TBST, and incubated with the
primary antibodies (pSer137-Pfn1 at 1:1000; pSer784-VCP at 1:50) in blocking buffer at 4C overnight. After TBST wash, they were
incubated with HRP-conjugated secondary antibodies (SignalStain Boost IHC Detection Reagent Mouse, #8125 and rabbit,
#8114) for 2hr at room temperature, and washed with TBST. They were developed using the ImmPACT DAB kit (Vectorlabs, SK-
4105), counterstained with hematoxylin, dehydrated, and mounted. Bright field images were taken on an upright BX51 fluorescence
microscope using the CellSens software. Nuclear staining was scored using the Allred scoring system, defined as the sum of the
scores for average intensity (0: non, 1: weak, 2: moderate, 3: strong) and proportion of positive nuclei (0: none, 1: < 1%, 2: 1-10
%, 3: 10%–33%, 4: 33-66 %, 5: > 67%) scores (Harvey et al., 1999).
Immunofluorescence staining and image acquisition
Cultured cells grown on plastic or poly-D-lysine-coated glass coverslips were treated with vehicle (H2O or DMSO) or DNA damaging
agents (in H2O or DMSO) for various times, rinsed with PBS, and fixed by 4% paraformaldehyde at room temperature for 20min. For
detergent pre-extraction, cells were incubatedwith cytoskeletal buffer (25mMHEPES, pH 7.5, 50mMNaCl, 1mMEDTA, 3mMMgCl2,
300mM sucrose and 0.5% Triton X-100) for 1-5min, followed by PBS rinse and fixation with 4% paraformaldehyde. They were
washed 4x with PBS/0.1% Triton X-100, blocked with 5% normal goat serum and 2% bovine serum albumin (BSA) in PBS/0.1%
Triton X-100. Primary antibodies (pSer137-Pfn1 at 1:1000; pSer784-VCP at 1:500; 53BP1 at 1:1000; gH2AX at 1:1000; BRCA1 at
1:1000; NBS1 at 1:500; pSer1981-ATM at 1:1000 in the same blocking buffer were added and incubated at 4C overnight. Cells
were washed 4x with PBS/0.1% Triton X-100, and incubated with Alexa 488 or 594-conjugated secondary antibodies in the same
blocking buffer for 2hr at room temperature. Theywere subsequently washed, counterstainedwith DAPI (1mg/ml), andmounted using
the ProLong Gold antifade reagent (Invitrogen). Fluorescent images were acquired on an inverted Olympus IX70 and an upright BX51
fluorescence microscopes using the CellSens software.





Cells (5-103 106) were harvested by scraping in PBS, and pelleted at 500 g for 5min at 4C. For native conditions, they were lysed by
200-500ml ice-cold 1x RIPA buffer (CST, #9806) with added protease (Pierce, A32955) and phosphatase inhibitors (Pierce, A32957) or
fractionated to obtain the nucleoplasm (see below for details). For denaturing conditions, they were suspended in 50ml pre-heated
lysis buffer (1% SDS, 20mM Tris-HCl, pH 7.4, 150mM NaCl), heated at 95C for 10min, and diluted 20-fold with ice cold buffer con-
taining 20mM Tris-HCl, pH 7.4, 150mM NaCl, protease and phosphatase inhibitors. Samples under native or denatured conditions
were clarified at > 16,000 g at 4C for 10min and supernatants were mixed with agarose pre-conjugated with various primary anti-
bodies (10-20ml agarose with 1-10mg antibodies per sample) for 2-4hr at 4C by gentle rotation. For sequential immunoprecipitations,
supernatant from the first pulldown was collected by gently pelleting the beads (500 g, 5min), and added to the second antibody.
Beads were washed and samples were denatured in SDS sample buffer.
Mass spectrometry
The unknown 100kDa protein band induced by DNA damage and immunoprecipitated by the pSer137-Pfn1 antibody was excised
from silver-stained SDS gel and subjected to standard in-gel trypsin digest as previously described (Held et al., 2013). Tryptic pep-
tides were analyzed on a TripleTOF 5600 nano LC-MS system (AB SCIEX). Mass spectrometry data were searched against the Uni-
prot Human Reference Proteome using Mascot to identify proteins. Search parameters were 25 ppm mass tolerance (MS1), 0.1
dalton (MS2), 2 missed cleavages and trypsin/P protease specificity, fixed carbamidomethylation (Cys) and variable methionine
oxidation and protein N-terminal acetylation.
Subcellular fractionation
Cells were scraped from tissue culture dishes after rinsing with PBS and centrifuged for 5min at 500 g at 4C, and subjected to frac-
tionation using the protocol described byMe´ndez and Stillman, 2000. Briefly, cell pellets (2-53 106) were resuspended in 200ml buffer
A (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.34 M Sucrose, 10 % Glycerol, 1 mM DTT, Protease and Phosphatase in-
hibitor cocktails), and Triton X-100 was added to a final concentration of 0.1%. After 8min incubation on ice, samples were centri-
fuged at 1,300 g at 4C for 5min, and supernatant was removed and saved as cytosolic fractions. Pellets were washed once with
buffer A without Triton X-100 and centrifuged at 1,300 g again at 4C for 5min. Supernatant was removed and discarded, and
100ml buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, Protease and Phosphatase inhibitor cocktails) was used to resuspend the
pellets. Samples were incubated on ice for 30min with intermittent mixing, and centrifuged at 1,700 g at 4C for 5min. Supernatant
was removed and saved as the nucleoplasmic fraction. Pellets were washed once with buffer B and centrifuged again at 1,700 g at
4C for 5min. Supernatant was discarded and pellets were solubilized in SDS sample buffer as the chromatin fraction.
Laser Microirradiation
A customized laser microirradiation system consisting of an inverted microscope (Nikon), a laser ablation unit (Photonic Instruments)
and microscope automation and imaging software (Metamorph, Molecular Devices) was used. To introduce DNA damage to cells, a
551-nmdye laser was directed to irradiate cells cultured on 35-mmglass-bottomed dishes (MatTek Cultureware, P35G-15-14-C) in a
line pattern. The laser energy delivered to each focused spot was set by an attenuator plate (50% transmission) and the number of
pulses per spot. Cells were laser irradiated at the confluency of 50%, fixed, and immunofluorescence stained at different time points
following irradiation as previously described (Chen et al., 2013; You et al., 2005). Total VCP and pSer784-VCP primary antibodies were
used at 1:150, and NBS1 antibodies were used at 1:500. Cells were imaged using the Nikon microscope and MetaMorph software.
Comet assay
The experiment was performed using the kit for Single Cell Gel Electrophoresis Assay from Trevigen (cat # 4250-050-K). In brief, cells
were diluted to 13 105/ml in PBS, combined with pre-melt LMAgarose (at 37C) at a ratio of 1:10 (v/v) and immediately pipetted onto
CometSlide (50 ml). Slides were placed flat at 4C in the dark for 30min for sample adherence and subsequently immersed in 4C lysis
solution (cat # 4250-050-01) for 2h. Excess lysis buffer was drained, and slides were immersed in freshly prepared alkaline unwinding
solution, pH > 13 (200mMNaOH, 1mM EDTA) for 20 min at RT. They were then subjected to gel electrophoresis using with the same
alkaline electrophoresis solution at 21 V for 30 minutes. Slides were washed twice with dH2O and then 70% ethanol for 5 minutes.
Sampleswere kept at 37Cuntil the gel circle was completelymelted and stainedwith 100 mL 1xSYBRGold (diluted in TEBuffer, pH
7.5 containing 10 mM Tris-HCl pH 7.5 and 1 mM EDTA) for 30 min at RT. Slides were completely dried at 37C. Fluorescent images
were taken using the Cellsens software on a 10x objective of an Olympus IX70 microscope and analyzed by ImageJ under the Open-
Comet plugin (Gyori et al., 2014). Data were expressed by the tail DNA percentage (tail intensity out of total DNA intensity).
Colony formation assays
Cells were plated at low density (100-1000) in 24-well plates, allowed to adhere for several hours to overnight, and treated in tripli-
cates with various drugs for overnight unless otherwise specified. They were washed twice with PBS and maintained in drug-free
growth media for 10-14 days during which viable cells were periodically quantified using the Alamar blue assay. At the end of the
experiments, cells were fixed by 4% paraformaldehyde and stained by 0.001% crystal violet followed by bright field image acquisi-
tion. Colonies were manually counted or semi-automatically quantified based on colony area (Guzma´n et al., 2014).




QUANTIFICATION AND STATISTICAL ANALYSIS
Chi square or Fisher exact tests were used to examine associations between Allred scores of the nuclear staining with the pSer137-
Pfn1 antibody and standard clinicopathological variables. For univariate survival analyses, RFS, OS and BCSS were quantified by
Kaplan–Meier curves in the whole group and among different subgroups stratified according to estrogen receptor status, IHC sub-
type, or treatment. OS was defined as time from diagnosis to either death from any cause or to last follow-up. BCSS was defined as
time from diagnosis to either death caused by breast cancer or to last follow-up. RFS was defined as time from diagnosis to any
recurrence or to last follow-up. Significance of differences in survival was assessed by log-rank and Wilcoxon tests. For multivariate
analyses, Cox proportional hazardsmodels were used to assess the hazard ratio (HR) of different prognostic covariates with survival.
These covariates included pathological age at diagnosis > 50 years versus% 50 years, tumor grade (1 or 2) versus 3, nodal status
negative versus positive, tumor size T1 versus (T2 or T3), lympho-vascular invasion (negative versus positive), ER status (negative
versus positive), PR status (negative versus positive), HER2 status (negative versus positive). p < 0.05 was considered as statistically
significant. Analyses including multiple comparisons were adjusted for multiple testing using the Benjamini-Hochberg FDR method.
Numbers of the evaluable cases used in the final correlative analyses were depicted in the figures and tables. All statistical analyses
were performed using R software (version 3.5.2) and SPSS version 23.
The analysis of the BCCancer (BCCancer) series as described in the results section followed a training/validation approach used to
cross-validate findings and to avoid overfitting that could result from data-driven cut-point determination. This series was originally
divided into training (n = 2003) and validation (n = 1989) sets and each set was randomly selected to represent approximately 50% of
the total study population with balanced clinicopathological characteristics. Optimal cut-points determination and biomarker anal-
ysis in association with clinical outcomes were first assessed on the training set to generate a specific and limited set of hypotheses
for testing. After presentation at a minuted research group meeting, these were subsequently tested on the validation set by a
research team member different from the one who did the training set analysis. Only results that were found to be significant in
both training and validation sets were used for data interpretation and conclusions. For the robustness of our results and to ensure
that they are not affected by properties specific to the pre-specified training/validation sets, the split was repeated 500multiple times
randomly.
Unpaired Student’s t test was used to compare the effects between wild-type and mutant VCP on cell survival, pSer1981-ATM foci
formation, and levels of DNA break. P values < 0.05 were considered statistically significant. Linear regression was used to compare
the staining patterns between pSer137-Pfn1 and pSer784-VCP antibodies, with the R2 value reflecting the goodness of the fit. Details
can be found in figure legends.
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Fig. S1 Nuclear antigen recognized by the pSer137-Pfn1 antibody inversely correlates with breast cancer 
survival in the UBC series, related to Fig.1C and 1D. (A) Representative IHC images of cytoplasmic staining 
of breast tumors by the pSer137-Pfn1 antibody.  (B) Individual nuclear Allred scores of the UBC TMA series 
were used for Kaplan-Meier analysis for association with the overall (OS) and relapse-free survival (RFS). (C) 
Nuclear Allred scores from (B) were binarized into low vs. high groups and subjected to Kaplan-Meier analysis 
for association with RFS as in (B). (D) Samples in the UBC series were divided into estrogen receptor negative 
(ER negative) vs. positive (ER positive) sub-groups and subjected to the same survival analysis as in (C) using 
the binarized nuclear Allred scores. (E) Cytoplasmic staining of the UBC TMA by the pSer137-Pfn1 antibody 
was scored based on the percentage of positive cells (intensity was similar across tissues) into four groups (0-
10%, 11-33%, 34-66%, 67-100%). The scores were used in univariate Kaplan-Meier analysis for association 
with overall (OS), relapse-free (RFS), and breast cancer-specific survival (BCSS). Log-rank and Wilcoxon tests 
were used to generate the p values which were considered statistically significant when being less than 0.05.  
Scale bars, 10µm. 
 
 
Fig. S2 The association between the nuclear antigen recognized by the pSer137-Pfn1 antibody and breast 
cancer survival according to IHC subtype in the UBC series, related to Fig.1C and 1D. (A-C) The UBC 
series was divided into different breast cancer subtypes (luminal A, luminal B, HER2+, and basal) as previously 
described (Cheang et al., 2008; Goldhirsch et al., 2011).  Luminal A: ER+ and/or PR+, HER2−, and ki67<14%; 
luminal B: ER+ and/or PR+, HER2−, and ki67≥14% or ER+ and/or PR+, any ki67 and HER2+; HER2+:  ER-, 
PR-, HER2+; triple negative: ER-, PR-, HER2-; basal-like: ER-, PR, HER2- and [EGFR+ or CK5+].  Binarized 
nuclear Allred scores as described in Fig.S1C-S1D were subjected to univariate Kaplan-Meier analysis for 
association with overall survival (A), breast cancer-specific survival (B), and relapse-free survival (C). Log-
rank and Wilcoxon tests were used to generate the p values which were considered statistically significant when 





Fig. S3 Nuclear antigen recognized by the pSer137-Pfn1 antibody associates with worse outcome of breast 
cancer treated with chemotherapy in the BCCancer series, related to Fig.1E. (A) Binarized nuclear Allred 
scores (low vs. high) were used in the univariate Kaplan-Meier analysis of the BCCancer cohort for breast 
cancer-specific survival (BCSS), shown for the training (n=1311) and validation (n=1340) sets separately.  (B) 
The training set of the BCCancer series (n=1311) was divided into subgroups based on systematic adjuvant 
treatments and subjected to univariate Kaplan-Meier analysis for BCSS.  Shown here are the no treatment 
(n=562), tamoxifen (n=407) and chemotherapy plus tamoxifen (n=100) groups.  No validation for these 
treatment groups was performed due to the lack of statistically significant association between nuclear scores 
and survival. (C) Chemotherapy-treated cases within the whole BCCancer series (n=672) were divided into 
triple negative vs. non-triple negative subgroups and subjected to the same Kaplan-Meier analysis for the 
association between binarized nuclear Allred scores and BCSS.  Training, validation, and combined datasets are 
shown.  Log-rank and Wilcoxon tests were used to generate the p values which were considered statistically 
significant when being less than 0.05. Unadjusted P values for the outcome in the different treatment groups of 







Fig. S4 Genotoxin-induced nuclear antigen of the pSer137-Pfn1 antibody is not Pfn1, related to Fig.2A.  
(A) Different breast cancer cell lines were treated with DMSO or etoposide (5µM) for 6hr, followed by 
immunofluorescence staining using the pSer137-Pfn1 antibody. (B) HeLa cells were treated with various 
genotoxic agents (1mM HU, 1µM cisplatin, 1µM gemcitabine, 50µM 5-fluorouracil) for 16hr, followed by 
immunofluorescence staining using the pSer137-Pfn1 antibody and counterstaining by DAPI. Scale bars, 20µm. 
(C) HeLa cells were infected with a control shRNA or two shRNAs targeting human Pfn1. Western blot 
showing complete Pfn1 knockdown 4 days after infection.  (D) HeLa cells infected with two control shRNAs 
(shCtrl and shLacZ) and the two Pfn1-specific shRNAs were treated with 5µM etoposide for 6h, followed by 






Fig. S5 Identification and characterization of pSer784-VCP, related to Fig.2B-2D and Fig.3. (A) BT549 
cells were treated with DMSO, 5µM etoposide, and 1mM HU for 12hr, followed by Western blot analysis using 
the pSer137-Pfn1 antibody. (B) MDA-MB-231, T47D, and MCF-7 cells were treated with DMSO or 200nM 
SN38 for 16hr, followed by Western blot analysis using the pSer137-Pfn1 antibody.  Red arrowheads indicate the 
DNA damage-induced 100kDa protein. (C) HeLa cells were treated with 200nM SN38 for 16hr, lysed in SDS-
free RIPA, and treated with or without alkaline phosphatase (AP) at 37°C for 1hr.  Lysates were 
immunoprecipitated by the pSer137-Pfn1 antibody followed by Western blot analysis of proteins bound to the 
antibody and present in the inputs using a VCP-specific antibody. (D-E) HeLa cells were treated with DMSO or 
50µM etoposide for 24 hours, lysed in denaturing buffer (1% SDS, 20mM Tris-HCl, pH 7.4, 150mM NaCl), 
and heated at 95°C for 10min. Samples were diluted 20-fold with ice cold buffer containing 20mM Tris-HCl, 
pH 7.4, 150mM NaCl, protease and phosphatase inhibitors, and clarified at >16,000g for 10min. Supernatants 
were subjected to immunoprecipitation by control IgG or VCP pan antibody (D) or the pSer137-Pfn1 antibody 
(E). IP samples from (D) were analyzed by Western blot using the pSer137-Pfn1 or VCP pan antibodies. IP and 
input samples from (E) were analyzed by Western blot using the VCP pan antibody. (F) HeLa cells were 
infected with shLuc or two distinct shRNAs targeting human VCP. Western blot showing effective VCP 
knockdown after 4 days. Cells were treated with 5µM etoposide for 6hr followed by immunofluorescence 
staining by the pSer784-VCP antibody and counterstaining by DAPI. Scale bars, 10µm. (G) U2OS cells were 
treated with 50µM etoposide for 1hr, recovered for 90min, detergent-extracted, fixed, and subjected to double 
immunofluorescence labeling using the pSer137-Pfn1 (rabbit, detecting pSer784-VCP) antibody and a BRCA1-
specific (mouse) antibody. DAPI was used for counterstaining. Representative images showing partial co-
localization of pSer784-VCP and BRCA1 in DNA damage foci of <10% of the cells and no co-localization in 





Fig. S6 pSer784-VCP is a late DDR event, related to Fig.4. (A-B) U2OS cells were laser micro-irradiated, 
fixed at different time points, and subjected to double immunofluorescence staining using the pSer784-
VCP/NBS1 (A) or VCP/NBS1 (B) antibody pairs. Scale bars, 10µm. (C) HeLa cells were treated with 10mM 





Fig.S7 Effects of Ser784 phosphorylation on VCP substrates, related to Fig.5 and Fig.6. (A) RIPA lysis of 
HeLa cells as described in Fig.5B.  Samples were blotted for tubulin (soluble marker) and histone H3 (insoluble 
marker). (B) HeLa samples from Fig.5C were blotted for tubulin (cytosolic marker), PELP1 (nuclear marker), 
and histone H3 (chromatin marker). (C) Equal numbers of HeLa cells were treated with 5µM NMS-873 for 1hr 
and subjected to subcellular fractionation. Cytoplasm, nucleoplasm, and chromatin fractions were analyzed by 
Western blot using an antibody specific to K48-linked polyubiquitin. (D) U2OS cells stably expressing GFP or 
RNAi-resistant VCP-GFP (WT or mutants) were infected with shLuc or shVCP#1 and #2 combined. Cells were 
analyzed 4 days later by Western blot using antibodies against VCP (detecting both endogenous VCP and 
exogenous VCP-GFP) or actin. (E) Cells in (G) were treated with 50µM etoposide for 30min, recovered for 1hr, 
and subjected to subcellular fractionation followed by Western blot analysis of the cytoplasmic, nucleoplasmic, 
and chromatin fractions using the K48-ubiquitin antibody controlled by GAPDH, actin, and histone H3. (F) 
RIPA lysed HeLa samples from Fig.5E were blotted for tubulin (soluble marker) and histone H3 (insoluble 
marker). (G) HeLa cells expressing RNAi-resistant wild type or mutant VCP were infected with shVCP #1, 
treated with 50µM etoposide for 30min, recovered for 2h in the presence of 20µM MG-132, and subjected to 
RT-qPCR for HIF1 using GAPDH for normalization. Shown are mean ± SD of three technical replicates of 
one biological replicate.  (H) RIPA lysed HeLa samples from Fig.6C were blotted for tubulin (soluble marker) 
and histone H3 (insoluble marker). (I) Nucleoplasmic and chromatin fractions of HeLa cells from Fig.6D were 
blotted for histone H3. Note that for (A, B, F, H, I) same samples from the experiments described in the main 






Fig. S8 Ser784 phosphorylation reduces VCP interaction with cofactors NPL4/UFD1 and K48-
polyubiquinated proteins, related to Fig.6. (A) HeLa cells were treated with 5µM etoposide or 1mM HU for 
20hr, lysed with SDS-free RIPA buffer, and immunoprecipitated by either the pSer784-VCP antibody or a pan 
VCP antibody. Antibody-bound proteins were analyzed by Western blot for K48-ubiquitin, total VCP and 
pSer784-VCP. Same amount of control IgG was used to bind the etoposide-treated HeLa samples to control for 
non-specific binding.  (B) MDA-MB-231 cells were treated with 5µM etoposide for 22hr, lysed, and 
immunoprecipitated by the VCP or pSer784-VCP antibodies, controlled by non-specific IgG as in (A). Samples 
were analyzed by Western blot for K48-ubiquitin, NPL4, and UFD1. Total VCP bound by the antibodies were 
visualized by silver staining. (C) Western blot showing similar expression levels of VCP-FLAG (WT and 
mutants) relative to endogenous VCP in the stable MDA-MB-231 cells. YFP-FLAG was expressed as a control.  
(D) MDA-MB-231 stable cells from (C) were treated with DMSO or 5µM etoposide for 12hr, subjected to 
chromatin fractionation, and analyzed by Western blot using anti-VCP or FLAG antibodies, with histone H3 as 









Fig. S9 Effects of Ser784 phosphorylation of VCP on PIKK signaling, related to Fig.7A. (A) MDA-MB-231 
cells were pre-treated with NMS-873 for 30min followed by 20min treatment with 25µM etoposide. Cells were 
lysed by SDS-free RIPA buffer, and soluble fractions were analyzed by Western blot for the indicated proteins.  
Red asterisks indicate pS/TQ motif-containing proteins whose levels are reduced by NMS-873. (B) HeLa cells 
stably expressing GFP or VCP-GFP (WT and mutants) were infected with shLuc, shVCP #1, or shVCP #2 
individually. Four days later, they were treated with 1mM HU for 4hr, lysed by SDS-free RIPA buffer, followed 
by Western blot analysis of the soluble proteins with the indicated antibodies. (C) VCP knockdown and rescue 
HeLa cells were treated with 50µM etoposide for 30min, recovered for 1hr, and subjected to cellular 
fractionation. Nucleoplasm and chromatin fractions were analyzed by Western blot using the indicated 
antibodies. PELP1 and histone H3 were blotted as loading controls. (D) VCP knockdown and rescue HeLa cells 
were treated with 5mM HU for 4hr and subjected to cellular fractionation and Western blot for ATR similarly to 
(C).  (E) Nucleoplasm and chromatin fractions from (C) were loaded proportionally to show the relative 
abundance of total ATM in either compartment. (F) VCP knockdown and rescue HeLa cells were treated for 
15min with 50µM etoposide, recovered for 1hr or 2hr, detergent extracted, fixed with para-formaldehyde, and 
immunostained for pSer1981-ATM. Shown are single biological replicates containing ~2000 cells per condition. 
Error bars represent SD. Similar results were confirmed by three biologically independent experiments. P values 






Fig. S10 Ser784 phosphorylation is important for VCP function specifically in the presence of genotoxic 
stress, related to Fig.7B. (A) HeLa cells stably expressing GFP or RNAi-resistant VCP-GFP (WT or mutants) 
were infected with shLuc or shVCP#1 and #2 combined.  Same number of cells were plated and grown without 
treatment for 10 days in colony formation assays.  (B) HeLa and U2OS stable cells expressing GFP or RNAi-
resistant VCP-GFP (WT and mutants) were infected with shVCP #1 and #2 combined and grown in colony 
formation assays for 10 days as in (A).  Viable cells were quantified by Alamar blue.  (C) Stable U2OS cells 
expressing RNAi-resistant VCP-GFP (S784A vs. S784D) were infected with shVCP#2 for 4 days, treated with 
vehicle or PARP inhibtiors olaparib or niraparib at the indicated concentrations for 16hr, and allowed to grow in 
colony formation assays for 10-14 days. Colonies were stained and quantified, and relative survival was 
calculated by normalizing drug-treated values over vehicle controls. (D) Stable HeLa cells expressing RNAi-
resistant VCP-GFP (S784A vs. S784D) were infected with combined shVCP#1 and shVCP#2, treated with HU 
and 5FU at the indicated concentrations for 16hr, and subjected to colony formation for 7-10 days and 
quantification as in (C). Values in (B-D) represent mean ± SEM of three technical replicates of single 
experiments. Results were confirmed by three biologically independent experiments. P values were based on 






















Table S1: Distributions of the level of the nuclear antigen of pSer137-Pfn1 antibody in the UBC series, 




Allred score Nuclear Allred scores of the antigen of the pSer137-Pfn1 antibody 
Allred 0 117 (39.67%) 
Allred 2 0 (0%) 
Allred 3 74 (25.08%) 
Allred 4 63 (21.35%) 
Allred 5 24 (8.14%) 
Allred 6 13 (4.41%) 
Allred 7 4 (1.35%) 




Allred score (0-3) 
(n=191) 
Allred score (4-
8)   (n=104) 
Total (n=295) P-value 
Age, years    0.80 
<50  19 (15%) 14 (13%) 33 (14%)  
≥50  111 (85%) 90 (87%) 201 (86%)  
Tumor Size, cm    0.55 
≤2 19 (11%) 14 (13%) 33 (12%)  
>2 153 (89%) 90 (87%) 243 (88%)  
Involved lymph 
nodes 
    
Negative 128 (67%) 61 (59%) 189 (64%) 0.14 
Positive 62 (33%) 43 (41%)  105 (36%)  
Tumor grade    0.02 
1 44 (24%) 11 (11%) 55 (19%)  
2 70 (37%) 42 (40%) 112 (38%)  
3 74 (39%) 51 (49%) 125 (43%)  
Lympho-vascular 
Invasion 
   0.16 
Negative 144 (79%) 72 (71%) 216 (76%)  
Positive 39 (21%) 29 (29%) 68 (24%)  
ER Status    0.81 
Negative 38 (20%) 22 (21%) 60 (31%)  
Positive 152 (80%) 82 (79%) 134 (69%)  
PR Status    0.20 
Negative 57 (30%) 39 (38%) 96 (33%)  
Positive 132 (70%) 65 (62%) 197 (67%)  
HER2 Status    0.28 
Negative 176 (95%) 91 (92%) 267 (94%)  



















Table S2: Clinicopathologic characteristics of the nuclear antigen of the pSer137-Pfn1 antibody in the 













pSer137-Pfn1 (nuclear) 2.4 1.3 4.4 < 0.01 








pSer137-Pfn1 (nuclear) 2.51 1.31 4.83 < 0.01 
Age 1.06 1.03 1.09 < 0.01 
Tumor grade 1.29 0.60 2.80 0.05 
Nodal status 1.15 0.54 2.45 0.07 
Tumor size 1.46 1.19 1.80 < 0.01 
Lympho-vascular invasion 2.82 1.37 5.82 < 0.01 
ER status 0.92 0.33 2.57 0.09 
PR status 0.61 0.27 1.42 0.03 
HER2 status 1.57 0.49 5.08 0.05 
 
Table S3: Univariate and multivariate analysis of overall survival (OS) for the level of the nuclear antigen 





Ki67    0.66 
<14% 111 (59%) 59 (57%) 170 (58%)  
≥14% 76 (41%) 45 (43%) 121 (42%)  
IHC Subtype     
Luminal A 99 (55%) 52 (53%) 151 (54%) (Luminal A vs. 
others) = 0.82 
Luminal B (high 
Ki67, HER2-) 
46 (25%) 24 (24%) 70 (25%) (Luminal B vs. 
others) = 0.94 
Luminal B (HER2+) 4 (2%) 2 (2%) 6 (2%)  
Her2-Enriched 5 (3%) 6 (6%) 11 (4%) (Her2-
Enriched vs. 
others) = 0.20 
Triple Negative  27 (15%) 15 (15%) 42 (15%) (Triple 
Negative vs. 
others) = 0.90 
Basal-like 18 (10%) 10 (10%) 28 (10%) (Basal-like vs. 





















Table S4: Univariate and multivariate analysis of breast cancer specific survival (BCSS) for the level of 
the nuclear antigen of pSer137-Pfn1 antibody in the UBC series, related to Fig.1C and 1D. 
 
 








pSer137-Pfn1 (nuclear) 2.55 1.51 4.33 < 0.01 








pSer137-Pfn1 (nuclear) 2.30 1.31 4.04 < 0.01 
Age 1.00 0.98 1.03 0.08 
Tumor grade 1.13 0.61 2.10 0.07 
Nodal status 1.19 0.62 2.29 0.06 
Tumor size 1.29 1.09 1.52 < 0.01 
Lympho-vascular invasion 2.10 1.09 4.06 < 0.01 
ER status 0.95 0.38 2.33 0.09 
PR status 0.73 0.34 1.56 0.04 
HER2 status 1.49 0.54 4.12 0.04 
 
Table S5: Univariate and multivariate analysis of relapse free survival (RFS) for the level of the nuclear 












pSer137-Pfn1 (nuclear) 2.39 1.15 4.97 < 0.01 








pSer137-Pfn1 (nuclear) 2.30 1.03 5.10 < 0.01 
Age 1.02 0.99 1.06 0.02 
Tumor grade 1.70 0.68 4.25 0.03 
Nodal status 1.56 0.60 4.07 0.04 
Tumor size 1.58 1.27 1.98 < 0.01 
Lympho-vascular invasion 2.93 1.20 7.15 < 0.01 
ER status 1.04 0.32 3.32 0.09 
PR status 0.58 0.21 1.59 0.03 














Table S6: Distributions of the levels of the nuclear antigen of pSer137-Pfn1 antibody in the BCCancer 
series, related to Fig.1E. 
Nuclear Allred scores of the antigen of the pSer137-Pfn1 antibody 
Allred score Training set  Validation set Combined set 
Allred 0 195 (14.9%) 183 (13.7%) 378 (14.3%) 
Allred 2 16 (1.2%) 19 (1.4%) 35 (1.3%) 
Allred 3 111 (8.5%) 138 (10.3%) 249 (9.4%) 
Allred 4 193 (14.7%) 193 (14.4%) 386 (14.6%) 
Allred 5 254 (19.4%) 246 (18.4%) 500 (18.9%) 
Allred 6 321 (24.5%) 314 (23.4%) 635 (24%) 
Allred 7 221 (16.9%) 247 (18.4%) 468 (17.7%) 
Allred 8 0 (0%) 0 (0%) 0 (0%) 








8)      (n=796) 
Total (n=1311) P-value 
Age, years    0.66 
<50  147 (29%) 218 (27%) 365 (28%)  
≥50  368 (71%) 578 (73%) 946 (72%)  
Tumor Size, cm    0.04 
≤2 281 (55%) 387 (49%) 668 (51%)  
>2 232 (45%) 406 (51%) 638 (49%)  
Involved lymph 
nodes 
   0.43 
Negative 267 (54%) 433 (57%) 700 (56%)  
1-3 142 (29%) 218 (29%)  360 (29%)  
4-9 66 (13%) 79 (11%) 145 (12%)  
≥10 17 (4%) 25 (3%) 42 (3%)  
Stage    0.36 
I 186 (36%) 264 (33%) 450 (34%)  
II 295 (58%) 473 (60%) 768 (59%)  
III 30 (6%) 58 (7%) 88 (7%)  
Tumor grade    0.002 
1-2 256 (52%) 331 (43%) 578 (46%)  
3 233 (48%) 435 (57%) 668 (54%)  
Lympho-vascular 
Invasion 
   1.00 
Negative 273 (55%) 421 (55%) 556 (44%)  
Positive 219 (45%) 337 (45%) 694 (56%)  
ER Status    0.02 
Negative 121 (24%) 237 (30%) 358 (27%)  
Positive 394 (76%) 557 (70%) 951 (73%)  
HER2 Status    0.001 
Positive  48 (10%) 125 (16%) 173 (13%)  














Table S7: Clinicopathologic characteristics of the nuclear antigen of the pSer137-Pfn1 antibody in the 
training set of the BCCancer series, related to Fig.1E. 
Ki67    0.18 
<14% 264 (56%) 391 (52%) 655 (54%)  
≥14% 205 (44%) 358 (48%) 563 (46%)  
Subtype    (Luminal vs. non-
luminal) = 0.004 
Luminal A 225 (44%) 306 (38%) 531 (41%)  
Luminal B 151 (29%) 242 (30%) 393 (30%)  
Her2-Enriched 22 (4%) 65 (8%) 87 (7%)   
Triple Negative  70 (14%) 138 (17%) 208 (16%) (Triple negative 
vs. non-triple 
negative) = 0.07 
Basal-like 34 (7%) 90 (11%) 124 (9%)  
Clinicopathologic 
characteristic 
Allred score (0-4) 
(n=533) 





Age, years    0.007 
<50  179 (34%) 215 (27%) 394 (29%)  
≥50  354 (66%) 592 (73%) 946 (71%)  
Tumor Size, cm    0.29 
≤2 285 (54%) 406 (51%) 691 (52%)  
>2 245 (46%) 395 (49%) 640 (48%)  
Involved lymph 
nodes 
   0.34 
Negative 285 (56%) 426 (55%) 711 (56%)  
1-3 158 (31%) 222 (29%) 380 (30%)  
4-9 48 (10%) 91 (12%) 139 (11%)  
≥10 15 (3%) 32 (4%) 47 (4%)  
Stage    0.22 
I 192 (36%) 258 (32%) 450 (34%)  
II 291 (55%) 478 (60%) 769 (58%)  
III 47 (9%) 65 (8%) 112 (8%)  
Tumor grade    0.001 
1-2 250 (49%) 312 (40%) 562 (43%)  
3 259 (51%) 474 (60%) 733 (57%)  
Lympho-vascular 
Invasion 
   0.65 
Negative 272 (53%) 404 (52%) 676 (52%)  
Positive 240 (47%) 378 (48%) 618 (48%)  
ER Status    <0.001 
Negative 102 (19%) 267 (33%) 369 (28%)  
Positive 429 (81%) 539 (67%) 968 (72%)  
HER2 Status    <0.001 
Positive  472 (90%) 653 (83%) 1125 (86%)  














Table S8: Clinicopathologic characteristics of the nuclear antigen of the pSer137-Pfn1 antibody in the 




























Table S9: Clinicopathologic characteristics of the nuclear antigen of the pSer137-Pfn1 antibody in the 




KI67    <0.001 
<14% 292 (60%) 377 (4%) 669 (53%)  
≥14% 197 (40%) 384 (51%) 581 (47%)  
Subtype    (Luminal vs. non-
luminal) < 0.001 
Luminal A 251 (51%) 295 (39%) 546 (40%)  
Luminal B 160 (33%) 230 (31%) 390 (28%)  
Her2-Enriched 22 (5%) 76 (10%) 98 (7%)   
Triple Negative  56 (11%) 153 (20%) 209 (15%) (Triple negative vs. 
non-triple negative) 
< 0.001 







Total (n=2651) P-value 
Tumor grade    <0.001 
1-2 506 (51%) 643 (41%) 1149 (45%)  
3 492 (49%) 909 (59%) 1401 (55%)  
ER Status    <0.001 
Negative 223 (21%) 504 (31%) 727 (27%)  
Positive 823 (79%) 1096 (69%) 1919 (73%)  
HER2 Status    <0.001 
Positive  926 (90%) 1310 (83%) 2236 (86%)  
Negative 99 (10%) 258 (17%) 357 (14%)  
Subtype    (Luminal vs. non-
luminal) <0.001 
Luminal A 476 (50%) 601(40%) 1077(41.3%)  
Luminal B 311 (32%) 472(31%) 783(30.1%)  
Her2-Enriched 44 (5%) 141(10%) 185(7.1%)   
Triple Negative  126 (13%) 291 (19%) 417 (16%) (Triple negative vs. 
non-triple negative) < 
0.001 
Basal-like 58 (6%) 195(13%) 253(9.7%)  
